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SUMMARY 
Sub-Saharan Africa (SSA) has a unique set of challenges pertaining to blood transfusion.  Two of the 
largest contributing factors are: (1) the most common disease states in SSA require large amounts of 
blood as a lifesaving intervention e.g. malaria, and (2) the highest burden of infectious diseases 
transmissible through transfusion (Tapko, Toure, & Sambo, 2014) is found in SSA.  This has often led 
to the dichotomous donor base that exists in SSA, consisting of Voluntary Non-remunerated Blood 
donors (VNBD) and family or replacement donors (FRD), since transfusion centres are unable to supply 
the demand when relying only on VNBD. 
VNBD are the safest blood donors as they have no monetary incentives and are under no direct social 
pressure to donate. Monetary incentives have been shown to entice individuals that know or suspect 
themselves to be infected with a blood borne agent to donate blood.   
Nucleic Acid Testing (NAT) in conjunction with serological testing is the gold standard for testing, 
however the vast distances and high temperatures of SSA makes transport of traditional plasma 
samples a logistical nightmare. Many publications evaluating the stability, suitability and ease of use of 
dried blood spot (DBS) and dried plasma spot (DPS) for NAT have been published. Generally results 
have been shown to be comparable to traditional plasma samples.  DBS are being used successfully 
in the early infant diagnosis (EID) programs for HIV by means of PCR testing especially in Africa.   
Ethical approval was obtained to conduct a study to determine whether DBS and/or DPS testing would 
be suitable for use in a resource limited setting for blood screening. 
Two cohorts were included.  Cohort A consisted of 900 de-identified negative new donor samples.  
Cohort B consisted of 100 de-identified confirmed positive donor samples, 9 procured reactive samples, 
and a contamination panel.  After routine donor testing was completed at Western Province Blood 
Transfusion Service, one DBS sample and one DPS sample for each blood donor was prepared and 
analysed with the Ultrio Elite Assay on the Panther analyser (Hologic Inc., USA). 
Logistically DBS/DPS is well suited for the resource-poor countries as samples are: 
a. Easy to obtain (fingerpick samples could be used).
b. Transport is simplified as samples will not leak or haemolyse due to high temperatures.
c. Samples can be stored at room temperature.
DBS/DPS samples demonstrated superb specificity.  DPS samples would be suited for screening blood 
and reduced cost involved in NAT testing provided that the HBV sensitivity is increased. Further detailed 
economic viability and large-scale studies need to be performed to determine sensitivity and specificity 
within a specific population. 
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OPSOMMING 
Bloedoortapping in Sub-Sahara Afrika(SSA) word geteister deur unieke uitdagings. Die twee grootste 
bydraende faktore is:  
1) die mees algemene infeksies in SSA vereis menige bloedoortappings as ingrypende lewensredende
en lewensverbeterende terapie bv. Malaria, 
2) die grootse las van aansteeklike siektes, wat deur bloedoortapping oorgedra word, word in SSA
aangetref (Tapko, Toure and Sambo, 2014). 
Hierdie twee faktore het bygedra tot die ontstaan van die tweeledigeskenskersbasis wat in SSA gevind 
word.  Die tweeledigeskenkersbais bestaan uit vrywillige onvergoede bloedskenkers(VOBS) en familie 
lede en/of vervangings skenkers(VS). Daar word dikwels staat gemaak op VS as gevolg van die feit dat 
bloedoortappingssentrums nie in staat is om die aanvraag te voorsien wanneer daar slegs op VOBS 
staat gemaak word nie. 
VOBS is die veiligste bloedskenkers omdat hulle geen monetêre motiewe het nie en onder geen direkte 
sosiale druk verkeer om te skenk nie. Monetêre motiewe kan individue, wie kennis dra of vermoed dat 
hulle bloed besmet is met oordraagbare agente, aanspoor om te skenk. 
Die kombinasie van nukleïensuurtoetsing (NAT) en serologiese toetsing is die goue standaard vir 
bloedoortappings-siftingstoetse, maar die lang afstande en hoë temperature van SSA maak die vervoer 
van tradisionele plasma monsters 'n logistieke nagmerrie. Menige publikasies oor die stabiliteit, 
geskiktheid en gemak van die gebruik van gedroogde bloed kol (DBK) en gedroogde plasma kol (DPK) 
vir NAT is reeds gepubliseer. Oor die algemeen het die resultate vergelykbaar met tradisionele plasma 
monsters vertoon. DBK word veral in Afrika suksesvol gebruik in die vroeë babadiagnose-programme 
(EID) vir die toetsing van menslike immuniteits virus deur middel van polimerase kettingreaksie. 
Etiese goedkeuring was verkry vir die studie wat beoog om te bepaal of DBK/DPK geskik sal wees om 
te gebruik vir siftings-bloedoortappingstoetse in 'n hulpbron beperkte omgewing. 
Twee kohorte was ingesluit by die studie. Kohort A het bestaan uit 900 gedeïdentifiseerde negatiewe 
nuwe skenkermonsters. Kohort B het bestaan uit 100 gedeïdentifiseerde bevestigde positiewe 
skenkersmonsters, nege aangekoopte reaktiewe monsters en 'n besmettings paneel. Nadat roetine 
siftings-bloedoortappingstoetse deur die Westelike Provinsie Bloedoortappingsdiens voltooi was, is een 
DBK monster en een DPK monster vir elke bloedskenker voorberei en getoets deur die Ultrio Elite 
reagens op die Panther instrument (Hologic Inc., VSA). 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
DBK/DPK is logisties geskik vir hulpbronbeperkte lande want die monsters: 
 
a. Is maklik om te verkry (Vingerprikmonsters kan gebruik word). 
b. Vervoer van monsters kan vereenvoudig word omdat monsters nie lek of hemoliseer weens 
hoë temperature nie. 
c. Kan teen kamertempuratuur geberg word. 
 
DBK/DPK het uitstekende spesifisiteit gedemonstreer (100%). DPK sal geskik wees vir die toeting van 
bloed en vermindering in koste verbonde aan NAT toetsing, slegs as die HBV sensitiwiteit verhoog 
word. Verdere ekonomiese, lewensvatbare en grootskaalse studies moet uitgevoer word om die 
sensitiwiteit en spesifisiteit binne 'n spesifieke bevolking te bepaal. 
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CHAPTER 1   
1. INTRODUCTION 
1.1. BLOOD TRANSFUSION 
1.1.1. Historical development 
The first recorded attempt at administration of blood took place in 1490 when an ill Pope Innocent VIII 
was given the blood of three young boys to “rejuvenate” him. However, the administration was not a 
success given that all 3 donors and the patient died.  It is still debated whether the blood was given to 
the Pope orally or intravenously (Wiener, 1933; Gear, 1938; Learoyd, 2006; ‘Highlights of Transfusion 
Medicine History’, 2018).  
 
After the unsuccessful attempt to save the Pope in the 15th century the transfusion scene was quiet until 
the early 17th century when various strides in the field where made. One of the most profound advances 
was made by William Harvey when he described the circulatory system and this enabled a quick 
succession of experiments. Richard Lower, an English physician, is credited with the first transfusion to 
animals.  He did ground-breaking experiments with dogs, first giving them transfusions of various 
liquors, and then graduating to giving the blood of one dog to another. His contemporary Denys read 
about Lower’s work and started to perform his own experiments transfusing blood from dog to dog.  
Denys submitted his report on his first lamb to human transfusion in July 1667, but due to publishing 
delays it was only printed after Richard Lower’s report of the same experiment, hence he is often not 
credited with the first blood transfusion to humans. (Learoyd, 2006)  The transfusion of animal blood to 
humans had dire consequences to the humans and was thus soon prohibited by law in England and 
France. After this law was passed we entered another lull of almost a hundred years in which no 
significant advances were made. 
 
James Blundell is credited with the first human to human transfusion, in 1818, after transfusing a patient 
for the treatment of post-partum haemorrhage. However, there is a record of an earlier transfusion, 
which was performed by an American physician Philip Syng Physick, in 1795. Unfortunately Physick 
never published and so is seldom recognised (or even mentioned) as a pioneer in this field. (‘Highlights 
of Transfusion Medicine History’, 2018) 
 
In the 20th century blood transfusion was revolutionised. In 1900 Karl Landsteiner, often referred to as 
the father of blood transfusion, and his team discovered the first three of the ABO blood groups, namely 
A, B, and O. This reduced transfusion fatalities significantly.  Group AB was discovered by the same 
team in 1902.  In 1914 the key to storing blood in glass bottles prior to infusion was found when the 
optimum dose of citrate for anti-coagulation was described. The first blood transfusion institute opened 
its doors in Moscow in 1926 led the Russian physician and scientist Alexander Bogdanov (Huestis, 
2007).  
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The World Wars necessitated a large number of advances in blood transfusion techniques, 
apparatuses, and biomedical consumables. Most notably the use of acid-citrate-dextrose (ACD) and 
the freeze drying of blood plasma were introduced.  In South Africa the Cape Peninsula Blood 
Transfusion Service was founded in 1938 (now known as the Western Province Blood Transfusion 
Service) at Groote Schuur Hospital. In 1940 Dr Phillip Levine and his colleagues describe what we now 
know to be the ‘Rh’ blood group system (Giblett, 1994) which was described as the main cause of 
haemolytic disease of the new born (HDN). In 1950 another remarkable change took place.  This was 
the change from fragile, re-usable glass bottles to disposable, breakage-resistant plastic bags for the 
collection of blood.  This change furthermore facilitated the introduction of component therapy as 
opposed to whole blood transfusions. 
 
In 1947 the first routine testing on units was introduced. Initially each unit was only tested for ABO and 
syphilis. In 1971 Hepatitis B surface antigen (HBsAg) testing was introduced, followed by the 
introduction of HIV testing in 1985, and Hepatitis C antibody (Anti-HCV) testing in 1990 (Aoki et al., 
1993; Van der Poel, 1999; Busch and Kleinman, 2009). This completed the current testing menu of 
recommended serological testing assays (World Health Organization, 2010). For the next 10 years 
serological assays were constantly reengineered to be more specific and sensitive without major 
reductions to the window periods to detect infections. In 2002 the first FDA licensed Nucleic acid 
amplification test (NAT) became available from Grifols, making accessible a test that by reducing the 
window periods for detection mitigates the risk related to acquiring a transfusion transmitted infection 
significantly (Cable, Lelie and Bird, 2013). 
  
1.1.2 Importance of blood transfusion 
Blood transfusion is seen world-wide as a life-saving, life improving medical intervention and treatment 
option.  Blood transfusions are indicated in various diagnosis.   
 
Red cell concentrates are predominantly used to increase oxygen carrying capacity when the patient’s 
ability to carry oxygen is impaired, e.g. following haemorrhage, bone diseases and certain deficiency 
disorders.  
Different plasma products are used to increase circulatory volume and to correct clotting factor 
deficiencies as result of hereditary factor deficiency disorders, warfarin overdose or the effect of 
massive transfusions. Plasma products are extensively used in burns patients.  
When a patient’s platelet count is low, these patients are at risk of excessive bleeding (World Health 
Organization, 2002). A low platelet count could result from chemotherapy, cancer and some infections 
in which case platelet products may be required. 
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1.2. RISKS ASSOCIATED WITH BLOOD TRANSFUSION 
1.2.1. General overview 
 
Although life-saving, blood transfusion does carry the risk of complications which include transfusion 
transmitted infections and adverse transfusion reactions.  
 
The main objective of blood transfusion policies are to ensure a safe and adequate blood supply 
appropriate to the needs of a country. Since less than half of the blood transfusion needs are being met 
in Sub Saharan Africa (SSA), in certain instances family replacement donors (FRD), paid donors (PD) 
and untested units are being transfused.  To address this problem the WHO established the Blood 
Safety Unit.  This unit has been tasked with assisting member states by providing basic guidelines to 
ensure all individuals have access to: 
 an adequate blood supply 
 at affordable prices 
 as safe as possible for transfusion ( within economic reason restraints) 
 transfused only when needed (clinically indicated transfusion) 
 within a sustainable blood transfusion program (Fleming, 1997)  
 
The WHO has recommended the development of national blood policies. This requires that each 
country develop a strategy for testing, recruiting and maintaining adequate blood supplies.  Although 
formal policies have been developed in 40 reporting countries only 22 countries have successfully 
implemented them. 
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1.2.2. Infectious risks 
Infectious risks vary from transfusion service to transfusion service.  A large percentage of the risk is 
mitigated by the screening assays used in the transfusion service. However, diseases that are not 
routinely screened for in blood transfusion testing do pose an additional infection risk. 
 
Table 1.1:  Infectious agents are known or present a theoretical risk to be transmitted through 
transfusion:(Kaur and Basu, 2005; Bihl et al., 2007; CDC, 2013; Fung et al., 2014) 
  
Viral agents Parasitic diseases/  
Bacterial agents 
Prion diseases 
Hepatitis A  
Hepatitis B (HBV) 
Hepatitis C (HCV) 
Hepatitis D  
Hepatitis E  
Human Immunodeficiency virus 
(HIV) 
Human T Lymphocytic virus  
Epstein Barr Virus 
Cytomegalo virus  
Dengue Virus  
Chikungunya virus 
St Louis encephalitis virus  
Human herpesvirus 8  
Human Herpesvirus 6 
Human parvovirus B19 
Simian foamy virus 
West Nile Virus 
Transfusion transmitted Virus  
SEN Virus  
Chagas Disease 
Treponema Pallidum 
Plasmodium species 
Trypanosoma cruzi 
Barbesia secies 
Leishmania species 
Borrelia burgdorferi 
Toxoplasma gondii 
Filarial infections 
Anaplasma phagocytophilum  
Rickettsia rickettsii 
 
 
Creutzfeldt-Jakob disease 
Human variant Creutzfeldt-Jakob 
disease 
Chronic wasting disease 
 
There are a number of reasons why blood donors are not screened for all transfusion transmitted 
diseases (TTD): 
1. no screening assay exists for the TTD,  
2. the incidence of the TTD is so low that screening would not be feasible, 
3. the prevalence of the TTD is so high that most donors would be excluded (e.g. Malaria),  
4. the costing of the screening assays is prohibitive, 
5. and lack of expertise, to name a few.  
 
In situations where there is no available test or it is not feasible to screen for a TTD marker, screening 
is often performed during donor interviews. This would then initiate deferrals for certain aspects, i.e. 
travel. 
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For an infectious agent to be transmissible through blood transfusion the agent must: 
 be present in the plasma or cellular component of the donated blood. 
 be able to use the blood stream as an entry point to the host. 
 have an asymptomatic stage of the disease i.e. exist where the infected donor is free from 
signs or symptoms of the infection. (Government of Maharashtra Blood transfusion Council, 
2005) 
1.3. BLOOD BORNE VIRUSES 
1.3.1 HIV 
Human immunodeficiency virus is a member of the Retroviridae family.  The virus infects certain human 
immune system cells which impair and destroy the functionality of these cells. As cell-mediated 
immunity is progressively lost susceptibility to infections increases. The virus is transmitted through 
contact with the blood or other body fluids of an infected person. 
 
The infectious dose, where 50% of the population (ID50) would acquire HIV, from a red blood cell 
concentrate (RCC) is calculated at 316 copies (Weusten et al., 2011; Vermeulen et al., 2013, 2014).  
Different viral loads could result in an infection because the plasma content of varies between products.  
The ID50 is calculated based on 20 mℓ of plasma within a RCC.  
 
High viral replication takes place during the initial acute phase of the HIV infection. This results in a 
peak of HIV-RNA within the first few weeks of being infected.  This peak is seen during or prior to the 
development of the p24 antigen and HIV antibodies as illustrated in Figure 1. 1.  
 
 
Figure 1. 1. The sequence of appearance of laboratory markers of HIV infection. This figure 
based on  (Grant and Smith, 2015) 
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1.3.2 Hepatitis B 
Hepatitis B virus is a member of the Hepadnaviridae family. The virus infects the liver and causes both 
chronic and acute infection.  Chronic infection puts people at a high risk for liver cirrhosis and carcinoma. 
The virus is transmitted through contact with the blood or other body fluids of an infected person.  Within 
the SSA Hepatitis B is predominantly transmitted through horizontal infection in childhood, sexual 
transmission, and transfusion transmitted transmission (Maponga, 2012). 
 
With reference to blood transfusion, Hepatitis B has 2 different ID50‘s dependent on stage of the disease 
in the donor.  The first is attained during the initial window period (WP) in the pre-acute phase where 
3.16 copies are estimated to be the ID50 (Vermeulen et al., 2012). The second is attained during the 
occult WP (Anti-HBc positive) where the estimated ID50  is 100-fold higher at approximately 316 copies 
(Vermeulen et al., 2012). The lowest ID50 of 3.16 copies is used to simplify calculations of risk (Weusten 
et al., 2011). Plasma content varies for different blood products, consequently, different viral loads could 
result in an infection. Transfusion with fresh frozen plasma (FFP) increases the risk of infection by 
approximately 9 times (Busch and Kleinman, 2009; Allain et al., 2013).   
 
In Figure 1. 2 the two WP are shown with corresponding viral markers. 
 
 
 
 
 
Figure 1. 2.  Recovered and occult hepatitis B infection base on (candotti and laperche, 2018) 
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1.3.3 Hepatitis C 
Hepatitis C virus is a member of the Flaviviridae family. Similarly to Hepatitis B, the virus causes liver 
disease that can be both chronic and acute. Chronic infections often develop into cirrhosis or liver 
cancer. The virus is transmitted through contact with the blood of an infected person.  The infection is 
often associated with intravenous drug use, and transfusion of untested units. The risk of infection due 
to sexual transmission is low.  Within SSA it is estimated that the overall prevalence of Hepatitis C is 
3 % (Madhava, Burgess and Drucker, 2002). 
 
In reference to blood transfusion, Hepatitis C, like Hepatitis B, has 2 different ID50’s.  The first ID50 is 
attained during the initial WP in the pre-acute phase where 3.16 (1-10) copies is estimated, this would 
be the worst case scenario.  The second ID50 is calculated to be 316 (100-1000) copies during the anti-
HCV positive stage since the anti-HCV provides some protection for the recipient (El Ekiaby et al., 
2015). 
 
In Figure 1.3 recovering and chronic infection periods are shown with the relevant viral markers. 
 
 
Figure 1.3.  Graph depicting of recovering and chronic infection periods of Hepatitis C  
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1.4. RESEARCH RATIONALE  
1.4.1   Blood transfusion in Africa 
1.4.1.1. History 
Blood transfusion has been practised in Africa since the early 1920s (Schneider, 2013). Organised 
blood services existed in SSA before World War II. These transfusion services were able to call on 
donors when patients required blood transfusions. The availability of doctors and facilities were the only 
limiting factor to performing transfusions during this time.  
After independence, various SSA countries moved away from centralised testing. Regional services 
were established in a response to high costs, large transport distances and delays, limited blood 
supplies, and political unrest.  Larger facilities where able to ensure limited blood transfusion services, 
however smaller hospitals could not meet demand.  The smaller, often rural, transfusion services were 
forced to turn to family/replacement donors (FRD) and even paid donors (PD) to supplement their blood 
stocks. (Schneider, 2013) 
A turning point was reached in transfusion testing when it became evident that HIV could be transmitted 
via blood transfusion, this led to international bodies such as the World Health Organisation (WHO) 
recognising that SSA needed help in order to ensure safe blood supplies. In 1994 it was noted that only 
ten out of 46 WHO SSA reporting countries could guarantee that blood had been screened for HIV 
(Tapko, Toure and Sambo, 2014). In response, the WHO has led various initiatives to increase blood 
safety in SSA. With the help of organisations such as PEPFAR, CDC and Safe Blood for Africa, some 
SSA countries have been able to improve their blood testing centres and staff education. In contrast, 
some SSA countries are still unable to meet even the most basic recommendations regarding blood 
transfusion and consequently do not have a sufficient, safe or sustainable blood supply. It has been 
estimated that less than 50% of blood transfusion needs are currently met in SSA (Tapko, Toure and 
Sambo, 2014).  
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1.4.1.2. Current status 
As a rule low-income countries have a higher disease prevalence than their higher income counterparts. 
Conversely, higher income countries often have a lower prevalence of TTDs than low-income countries.  
First world countries (with low TTD prevalence) are able to screen donated blood with the most 
sophisticated screening tests available.  In comparison, countries within the SSA (with a high TTD 
prevalence) are often unable to employ even the minimum screening recommendations.   
A myriad factors contribute to the insufficient, or lack of, screening. These include economic instability, 
civil wars, lack of infrastructure, manmade- and natural disasters. SSA carries 10% of the world disease 
burden, as well as the highest disease burden for TTDs (Tapko, Toure and Sambo, 2014).  In 2010 
approximately 68% of people living with HIV worldwide lived in SSA, in an area with only 12% of the 
global population (WHO, UNICEF and UNAIDS, 2011). Within the blood donor population, which is 
often seen as a safer/lower risk population, the prevalence of TTDs is higher in low-income countries 
than in high-income countries as illustrated in TABLE 1.2.   
Table 1.2.  Prevalence of transfusion-transmissible infections in blood donations (Median, 
Interquartile range (IQR), by income groups(WHO, 2016) 
 HIV HBV HCV 
High-Income 
countries 
0.003% 
(0.001% – 0.04%) 
0.03% 
(0.008% – 0.18%) 
0.02% 
(0.003% – 0.16%) 
Upper middle-
income countries 
0.08% 
(0.006% – 0.2%) 
0.39% 
(0.16% – 0.69%) 
0.21% 
(0.05% – 0.42%) 
Lower middle-
income countries 
0.20% 
(0.05% – 0.44%) 
1.60% 
(0.94% – 4.13%) 
0.40% 
(0.19% –1.5%) 
Low-income 
countries 
1.08% 
(0.56% – 2.69%) 
3.70% 
(3.34% – 8.47%) 
1.03% 
(0.67% – 1.80%) 
 
With TTD prevalence this high in low-income countries, even within the blood donor base, it can be 
assumed that incidence cases will be high.  Theoretically the implementation of NAT testing would 
provide greater benefit to low-income countries since NAT is able to detect infection during serological 
window periods which would be seen more frequently in high TTD prevalence countries (El Ekiaby, 
Lelie and Allain, 2010).  
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A large number of countries within SSA are unable to screen blood for transfusion in a quality assured 
manner. However, there are exceptions, some SSA countries have been able to increase their voluntary 
donations and improve their testing strategies. These countries have the potential to perform 
sophisticated centralised testing, but are still resolving terrain and infrastructure challenges, so small 
regional testing centres remain the norm. Some of these small testing centres have the capacity and 
ability to perform serological testing, but not yet NAT testing due to the infrastructure, expertise and 
cost involved. 
The difficulty of transporting traditional plasma samples across vast distances between rural areas and 
cities on poor condition roads makes this one of the biggest deterrents for centralised testing. An 
additional constraint is that traditional plasma samples require cold chain management increasing cost 
and transport difficulty. 
 
1.4.2. Blood safety in Africa 
Africa has a unique set of challenges pertaining to blood transfusion.  The two of largest contributing 
factors are:  
1. the most common disease states in SSA require large amounts of blood as lifesaving 
intervention e.g. malaria, 
2. the highest burden of infectious diseases transmissible through transfusion (Tapko, Toure and 
Sambo, 2014)is found in SSA.   
This has led to the dichotomous donor base that exists in SSA. The donor base consists of voluntary 
non-remunerated blood donors (VNBD) and family/replacement donors (FRD). Transfusion centres are 
unable to meet the transfusion demand when relying only on VNBD. 
VNBD are the safest blood donors as they have no monetary incentive, or direct social pressure to 
donate. Monetary incentives have been shown to entice individuals that know or suspect themselves 
to be infected with a blood-borne agent to donate blood. While VNBD are the safest donors, the effort 
and cost involved in testing, transport, donor retention and processing are often prohibitive in severely 
economically restrained countries.  In contrast, the cost of testing, processing and delivery of a unit from 
a replacement donor is about 4 times less than the cost of a voluntarily donated unit (Bates et al., 2008). 
The cost of a voluntarily donated unit is attributed to: the cost of running a testing facility utilising 
enzymatic or chemiluminescent immunoassays for screening for transfusion-transmitted infections 
(TTI); staff training and staffing costs; transport; donor management and donor recruitment. The lower 
cost of replacement donation is attributed to it being done in a hospital setting where only limited 
testing (often using lateral flow immunochromatographic/rapid point-of-care tests) is performed by 
hospital staff.  Subsequently, only 42.3% of countries reporting to World Health Organisation (WHO) 
collect more than 90% of their blood supply from VNBD and 41% of countries collect more than 50% 
of their blood supply from FRD (World Health Organization, 2016).  
Stellenbosch University  https://scholar.sun.ac.za
11 
 
 Blood transfusion testing in SSA can be roughly broken down into 2 categories: Hospital-Based and 
National blood transfusion services. See Error! Reference source not found. for comparison of the 
above mentioned categories.  
Table 1.3. Comparison of the two different transfusion testing categories 
 
Hospital- Based National blood transfusion services 
Donor Base 
These testing centres focus on FRD. 
FRD are donors who donate when 
someone known to them requires a 
transfusion.  FRD may unfortunately also 
include hidden paid donation as the donor 
may receive monetary contributions from 
the patient’s family to present as a family 
FRD when no other suitable donor can be 
found by the patient’s family (McCullough 
and McCullough, 2013; Asamoah-Akuoko 
et al., 2017) 
Rely on both VNBD and FRD 
Due to the cost involved with especially recruitment of 
VNBD less than 50 % of total blood donors on the 
African continent are VNBD.  In contrast countries like 
Ivory Coast, Malawi and Burkina Faso who receive 
external funding (Tagny et al., 2008) and other well 
established transfusion services like Uganda and 
South Africa are mostly or completely dependent on 
VNBD (Lund et al., 2013) 
Organisational 
structure 
Situated in hospitals both regional and 
remote. 
The testing centres are both regional and centralised. 
Blood stock 
They have limited blood stock and have 
limited ability to provide component 
therapy. 
Larger blood stocks are available in the larger 
academic or university affiliated hospitals.  However 
the amount of stored blood in SSA countries remains 
below the WHO minimum target for adequate blood 
supply (10 units per 1000 population per annum) with 
the exception of Botswana, Guyana, Namibia and 
South Africa (Chevalier et al., 2016) 
Testing 
Limited TTI testing is performed as it is not 
sustainable to test relatively small 
quantities of blood with automated 
analysers utilizing chemiluminescence 
(CLIA).  Rapid lateral flow tests (RDT) are 
used more frequently as these tests are 
readily available and require no 
equipment or electricity. However such 
rapid tests are usually less sensitive than 
laboratory-based and ensuring 
proficiency in conducting such tests is 
notoriously challenging. 
Larger testing centres use automated CLIA analysers 
and the more remote settings use enzyme-linked 
immunosorbent assays or RDT tests. 
NAT is performed in only a handful of countries in 
SSA as part of their blood screening strategy.  This is 
in contrast with the European blood transfusion 
services. However it has been reported that NAT 
would identify comparatively more HBV yield and 
occult cases in SSA and thus be more cost effective 
than in Europe (El Ekiaby, Lelie and Allain, 2010) 
Stellenbosch University  https://scholar.sun.ac.za
12 
 
1.4.3. Dried blood and plasma spots for nucleic acid testing  
In the last century applying biological fluids and/or blood to filter paper has changed a number of fields 
of study. This technique became widespread after Dr Robert Guthrie, in November 1961, found a novel 
way of screening for Phenylketonuria (PKU) (Robert Guthrie and Ada Susi, 1963). Guthrie was 
reportedly inspired by a Sherlock Holmes story where a desk blotter was used to solve a murder (Paul 
and Brosco, 2013). Dried blood spot (DBS) and dried plasma spot (DPS) sampling techniques have 
had a significant impact on, to name a few, forensic pathology, new-born metabolic screening, 
epidemiology, and drug analysis (Li et al., 2014).  
DNA extraction from dried blood spots on filter paper was first described in 1987 (McCabe et al., 1987). 
Many studies evaluating the stability, suitability, and ease of use of DBS for NAT have since been 
published. Results have generally shown to be comparable to traditional plasma samples testing. DBS’s 
success is attributed to the fact that it provides a robust sample that can be transported over large 
distance at temperatures at and above room temperature. This is essential in SSA where cold chain 
management of sample shipment and storage are challenging, and poor infrastructure results in 
adverse logistical issues. Agitation of the sample due to poor road conditions is not an issue with DBS. 
Table 1.4 describes the advantages and disadvantages of DBS/DPS as compared to traditional liquid 
plasma samples.  
Table 1.4.Advantages and disadvantages of DBS/DPS 
Advantages Disadvantages 
Robust sample 
DBS/DPS samples can be stored at ambient 
temperatures for up to 45 days without risking 
nucleic acid integrity 
Additional steps prior to testing 
Nucleic acids must first be eluted from DBS/DPS 
prior to testing 
Lower Infection risk 
The viral envelope is damaged during the drying 
process (although HBV may remain infectious for 
a week) (Bond et al., 1981). Thus, once dried, the 
biohazard is very low. 
Small sample volume  
A typical DPS contains 70 μl of plasma and a 
typical DBS 35 μl of plasma volume. Several 
DBS/DPS can be eluted together to increase the 
sample volume for testing. 
Sample  
No risk of sample leaking or breaking.   
The sample can be transported by normal mail as 
the dried blood matrix stabilises many analytes 
including DNA, infection risk is very low and the 
sample will not break and leak 
Possible lower sensitivity 
Due to the small sample volume and elution 
process, the sample might show lower sensitivity 
when compared to traditional liquid plasma 
samples. 
  
DBS are being used successfully in the early infant diagnosis (EID) programs for HIV by means of 
polymerase chain reaction (PCR) testing. As such DBS has revolutionised the EID program for HIV in 
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low-resource countries by reducing the cost and training involved in sample collection and transport.  
This reduction in cost has resulted in DBS being used extensively within limited resource settings 
allowing access to early diagnosis for infants and the required treatment, thus reducing morbidity and 
mortality in this population (Ciaranello et al., 2011). DBS testing in the EID program within SSA has 
predominantly been used in conjunction with PCR (Chibwesha et al., 2016) with manual or semi-
automated extraction processes (Stevens et al., 2009).  
The Procleix Ultrio assay menu includes two versions for the Panther instrument. The Procleix Ultrio 
blood screening assay for blood donors simultaneously detects the presence of HIV-1/2, HCV RNA and 
HBV DNA, using the multiplex TMA technology.  And the second is the Aptima assays (Aptima HIV-1, 
Aptima HCV and Aptima HBV) which are used during confirmation and identification of the virus of 
reactive Procleix Blood screening assay samples.  These have individual probes specific for each virus 
and helps discriminates between them. Evaluations of DBS/DPS have been done using Aptima HIV-1 
RNA qualitative assay (Sahoo et al., 2016). 
 
1.5. AIMS AND OBJECTIVE 
1.5.1. Aims 
The aim of this study is to validate a screening method using a novel sample type. We present the 
advantages of using this new method for screening donated blood for viral nucleic acid in resource 
constrained settings. 
1.5.2. Objective 
2. To demonstrate that dried blood spot (DBS) and / or dried plasma spot (DPS) testing is 
suitable for blood donor screening and can make good quality testing more widely available 
in SSA due to lowering costs.  
3. To determine the diagnostic sensitivity and specificity of testing DPS and DBS samples, in 
comparison to testing of plasma samples as per routine protocol. 
4. To determine the stability of DPS and DBS after being stored for three weeks at room 
temperature. 
 
1.5.3. Hypothesis 
1. DPS and DBS testing is compatible with the nucleic acid testing (NAT) platform used at WPBTS 
(Ultrio Elite assay on the Panther analyser). 
2. Interpreted test results obtained using DPS and / or DBS are comparable to conventional plasma 
sample testing. 
3. Sample stability is high over a limited period of time allowing DBS / DPS  to be transported to a 
centralised blood testing centre. 
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1.6. ETHICAL CONSIDERATIONS  
1.6.1. Routine informed consent  
Each donor routinely completes and signs a Donor Questionnaire Addenda A which covers health and 
lifestyle questions prior to donating blood.  In Point 1 of the consent section the donor gives consent for 
their blood to be tested for syphilis, Hepatitis B, Hepatitis C and HIV.  In point 3 the donor gives consent 
to having their samples/blood products used for research purposes.   
The tests being performed with the DBS /DPS are for the same three viruses (HIV, HBV and HCV) that 
are routinely screened each time a donor donates blood, i.e. no additional non-routine markers will be 
tested for. 
 
1.6.2. Confidentiality 
Samples will be de-identified prior to testing the DBS and DPS samples. At no time will a donor’s 
identification be made available to any third party involved or not involved in this study.  
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CHAPTER TWO 
2. RESEARCH DESIGN AND METHODOLOGY 
2.1. MATERIALS 
2.1.1. Ethical considerations 
2.1.1.1. Routine Informed consent  
At WPBTS blood donors are voluntary non-remunerated donors (VNRD) from within the borders of the 
greater Western Cape. This area is bordered by Plettenberg Bay, Springbok, and Beaufort West. Blood 
donors are recruited by blood drives, recruitment calls, recruitment SMS’ and at blood donor clinics. 
Within the Western Cape, approximately 1.5% of the population donates or has donated blood. In 2017 
70 140 donors donated, 20869 of which were first-time donors (Rix, no date).  The donor base for 2016-
2017 comprised of 49% females and 51% males, and included Asian (1%), Black (4%), Coloured (31%) 
and White (64%) donors. During this time WPBTS donors donated, on average, 2.17 donations per 
year. 
Each donor routinely completes and signs a Donor Questionnaire which covers health and lifestyle 
questions prior to donating blood (Addendum A). In Point 1 of the consent section the donor gives 
consent for their blood to be screened routinely for syphilis, Hepatitis B, Hepatitis C and HIV. In point 3 
the donor gives consent to having their samples/blood products used for research purposes.   
This study will establish whether the Ultrio Elite Assay can be used for blood screening using DBS/DPS. 
The tests performed with the DBS/DPS are for the same three viruses (HIV, HBV and HCV) that are 
routinely screened for each time a donor donates blood, i.e. no additional non-routine markers were 
tested for.  The only difference between routine testing and this study was the sample type. Published 
studies have shown that DBS and DPS are equally or slightly less sensitive than plasma testing 
(Stevens et al., 2008). 
 
2.1.1.2. Approval 
Ethical approval was obtained from the University of Stellenbosch Health Research Ethics Committee 
(HREC 1) via Minimal Risk Review procedures on 15 September 2017 (Addendum B). 
(Institutional Review Board (IRB) Number: IRB0005239. Protocol Reference number 0806.)  
 
2.1.2. Study Population 
The study population consisted of WPBTS blood donors that donated blood at the various blood 
donation clinics within the WPBTS donation area.  These donors included both first-time donors (ND) 
and repeat donors (RD) who donated from November 2017 until January 2018. 
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All samples were drawn as per routine donation procedure. No additional blood samples were drawn 
from donors.  The blood donor samples were first subjected to routine sample preparation which 
comprised of centrifugation. This was followed by routine testing which included NAT, serological, 
syphilis and blood group testing. Samples were stored in a refrigerated room after completion of testing, 
as per routine protocol.  Only once all routine testing was completed and confirmed, were the samples 
used for this study.  
 
At WPBTS all routine samples are interpreted using two separately completed algorithms. The two 
algorithms are the serological algorithm and the NAT algorithm. Only if the sample interpretation for 
both algorithms are the same, i.e. HIV reactive or non-reactive, is the sample regarded as a concordant 
reactive sample or concordant negative sample. All samples used in this study were categorised based 
on the WPBTS routine serological and NAT algorithms which are illustrated in Figure 2.1 and Figure 
2.2.  The Ultrio Elite is a multiplex assay which simultaneously detects RNA for HIV-1/2 and HCV, as 
well as HBV DNA, therefore discriminatory testing is performed as part of the NAT algorithm. The 
discriminatory probes discriminate which of the three viruses are responsible for the Ultrio Elite reactive 
result. The Discriminatory assays (dHXV) consist of 3 different discriminatory probes namely; the 
discriminatory probe for HBV (dHBV), the discriminatory probe for HCV (dHCV), and the discriminatory 
probe for HIV (dHCV). 
 
Figure 2.1.  Simplified routine WPBTS serological algorithm 
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Figure 2.2.  Simplified routine WPBTS NAT algorithm 
 
2.1.2.1. Cohort A  
This cohort consisted of 900 WPBTS routine first-time/new donors (ND) that were found to be negative 
on routine screening on the Panther analyser (Hologic Inc., USA). 
 
The rationale behind selecting new donors is that they are not prone to a preselection bias that would 
otherwise have occurred due to repeat ‘cross-reactive’ donors. A ‘cross-reactive’ donor is a donor 
whose blood results appear to be reactive at first but after repeat testing or confirmatory testing are 
shown to be non-reactive. According to international standards ‘cross-reactive’ units are not to be 
transfused and as such must be discarded. At WPBTS these repeat ‘cross-reactive’ donors are 
requested not to donate or refrain from donating for a specified time due operational guidelines and 
requirements, not due to a potential infection. As a result, these repeat donors (RD) with cross-reactive 
results are removed from the donor base which could then result in preselection bias if we used RD for 
this cohort. 
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2.1.2.2. Cohort B 
Cohort B consisted of reactive samples.  Within this cohort 3 different sample populations were used, 
namely:  
1. Contamination panel 
2. WPBTS reactive donor samples 
3. Procured samples 
2.1.2.2.1. Contamination panel 
A "contamination panel" consisting of 28 known positive plasma and twelve known negative plasma 
samples was run blind to control for possible carry-over from positive to negative samples. The panel 
contained samples positive for at least one of the viruses as determined by routine screening followed 
by confirmatory testing. The panel samples were numbered from A001 to A040 and were arranged in 
such a way that reactive samples would be processed directly after non-reactive samples and vice 
versa. The operator was blinded to the expected results until testing had been completed. The samples 
were handled using universal precautions.  The samples were prepared, which included the making of 
DPS on cards, elutions and processed in numerical order from A001 to A040.  Because only plasma 
samples were included in this panel only DPS was prepared. Reactive and non-reactive samples were 
prepared and processed on the same bench within one batch. In a real-world scenario results would 
not be available on donor samples prior to testing, therefore during this analysis reactive and non-
reactive samples were handled in the same batch. 
 
2.1.2.2.2. WPBTS donors found to be positive for viral markers on routine screening on the Panther 
analyser 
 
This sample population consisted of 100 WPBTS donors found to be positive for viral markers on routine 
screening on the Panther analyser. 
 
Due to the low prevalence of HIV, HBV and HCV among the donor population of WPBTS (799 donors 
out of 777 112 donations tested were found confirmed positive for any of the three viruses from 2013 
until 2017), it is realistic to assume that most WPBTS donors will be negative for the routine viral 
markers.  During the calendar year of 2017, 37 ND were found to be HIV positive (3 serology yields and 
2 NAT yields, 32 concordant positive) 2 ND were found to be concordant HCV positive, and 72 ND were 
found to be HBV positive(5 serology yields, 2 NAT yields and 65 concordant positive). The average 
prevalence for all three markers for ND in 2017 is 0.032.  In order to calculate diagnostic sensitivity, 
samples confirmed positive for one or more of the three viruses were included in the study. All confirmed 
concordant positive samples were confirmed by both serological screening on the cobas e602 system 
and the NAT testing on the Panther system. All confirmed NAT only positive samples were confirmed 
on the Panther system using samples of a different origin to exclude contamination.  
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2.1.2.2.3. Procured samples 
Due to the low prevalence of the three viral markers in the donor population, three reactive validation 
plasma samples, with known viral loads, were procured for HIV-1, HBV, and HCV respectively from 
the National Serology Reference laboratory (Fitzroy, Australia).  The objective of including these 
samples was to perform dilutions to determine the lowest level of detection/diagnostic sensitivity 
based on linear regression, as well as testing for stability after three weeks of storage. 
 
2.2. METHODS 
2.2.1. Study design 
Nine hundred negative ND samples and one hundred confirmed positive donor samples, as defined by 
routine blood safety screening done at WPBTS, were additionally screened for viral nucleic acid using 
a dried blood spot kit. The confirmed positive samples had a variety of sample to cut-off (S/CO) values 
on both serology and NAT.  After routine testing had been completed, one DBS sample and one DPS 
sample for each blood donor was prepared and analysed with the Ultrio Elite Assay on the Panther.  
Specificity was calculated based on Cohort A. Sensitivity was determined from the results of the reactive 
samples as well as the results of serial dilutions.  The serial dilutions of procured samples with 
quantitative viral load values were used to calculate linearity and determine analytical assay sensitivity. 
Serial dilutions were made from at least one sample per analyte with known viral loads. Figure 2.3 
illustrates the study design, algorithms used as well as the interpretation criteria. 
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Figure 2.3.  Flowchart of the study design, algorithms used and interpretation criteria  
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2.2.1.1. Specimen collection and preparation 
Donors that present at a blood donation clinic are asked to complete the WPBTS Health and Lifestyle 
Questionnaire. Thereafter the WPBTS clinic staff evaluate the answers on the questionnaires, if the 
staff are satisfied with the questionnaire the donor is registered.  Serial numbers are then placed on the 
relevant documentation and empty sample tubes. However, if the donor does not satisfy the donation 
questionnaire standards the donor will be deferred and no samples will be drawn. Point-of-care 
haemoglobin screening is performed on each registered donor by using the HemoCue machine 
(HemoCue AB, Ängelholm, Sweden). Only if the donor has a haemoglobin level of not less than 
12.5 g/dℓ for females and not less than 13.5 g/dℓ for males, will the donor be allowed to donate 
(Standards of Practive for Blood Transfusion in South Africa, 2017). 
 
Once a donor has been identified as being able to donate, serial numbers on the sample tubes are 
checked against the serial numbers on the Teruflex® blood pack (Terumo Penpol Private Limited, 
Thiruvananthapuram, India). The donor is then prepared for the donation event. The donor is identified 
by name and birthdate which is compared to the label on the questionnaire. The venepuncture site is 
cleaned with alcohol swabs and the needle is inserted into the donor’s arm at an approximate angle of 
25o using an aseptic technique. 
 
The pre-donation sampling pouch is filled first and clamped once it is appropriately filled. Three samples 
are drawn from the pre-donation sampling pouch of the Teruflex®. These samples are collected in 
ethylenediaminetetraacetic acid (K2EDTA) blood tubes manufactured by BD (Franklin Lakes, NJ USA).  
The Virology Department at WPBTS receives two of the three samples.  The two Virology samples are 
identical 10 mℓ samples with the only difference being that the cap colour is different for these two 
samples: purple and gold. The purple-capped tube (K2EDTA) is used for the serological viral marker 
screens on the Cobas c8000 system (Roche Diagnostics, Mannheim, Germany).  The gold-capped 
tube (K2EDTA) is used for the NAT on the Panther system (Grifols, CA, USA).  After routine NAT testing 
the remainder of the sample was used for this study. Prior to routine NAT testing, samples are 
centrifuged for 15 minutes at between 4134 and 4231 gs depending on the make of the centrifuge which 
is consistent with the Ultrio Elite recommendations for sample preparation (Gen-Probe, 2015). Samples 
are then processed for routine testing, after which samples are kept upright in a cold room at 2-8 oC for 
up to 7 days.  Within that period DBS/DPS were prepared for this study. The details and testing 
procedure flow chart is illustrated in Figure 2.4.  
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Figure 2.4.  DBS/DPS sample preparation and testing flow chart.  
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2.2.2. DBS/DPS  
2.2.2.1. Work area preparation 
The laboratory bench areas where reagents were prepared were decontaminated daily with 0.5% 
sodium hypochlorite solution which was left on the surface for 15 minutes and then wiped down with 
water. A separate sample preparation area was established and decontaminated daily in the same 
manner as the reagent area. 
 
2.2.2.2. Preparation 
A 50 µℓ donor sample was added to each of the five spots present on the Ilex DBS spot collection card.  
The card is made of Munktell TFN filter paper (Ahlstrom-Munksjö, Stockholm, Sweden) and has four 
perforated 12 mm circles for the addition of samples.  The fifth circle is not perforated and was kept in 
case of a discrepant result. Exactly 50 µℓ of plasma from the donor EDTA tube was pipetted onto each 
of the three of the five spots.  Subsequently, the sample was mixed with wooden applicator stick and 
50 µℓ whole blood was pipetted onto each of the other two spots.  A calibrated precision pipette with 
disposable tips was used. The cards were placed on empty Panther disposable pipette tip trays as 
these trays could be stacked in a manner which enabled proper ventilation. The tray stacks were stable 
ensuring that the cards stacks did not fall over and contaminate each other.  Samples were air dried for 
at least 24 hours prior to being eluted.  During the drying process, the biological material binds to the 
card but the water molecules evaporate allowing proteins and nucleid acids, inter alia, to stabilise.  
2.2.2.3. Elution of DBS/DPS  
A 2000 µℓ of sample transport buffer (Gen-Probe, San Diego, CA, USA) was pipetted into a 5000 µℓ 
screw top plastic tube. The sample transport buffer was a 110 mM lithium lauryl sulphate (LLS) Buffered 
Solution (‘GEN-PROBE ® APTIMA ® Adapter Kit’, 2011). A calibrated precision pipette using 
disposable tips was used.  
Serial numbers that correspond to the serial numbers of the samples on the cards were printed with 
either a B- or P- prefix denoting whether the sample was a dried blood or a dried plasma spot sample. 
Each card had both a P- and B- serial number. The corresponding set of serial numbers were then 
applied to the two plastic tubes containing the measured buffer solution. The corresponding spots were 
punched out straight into the tube containing the solution, using disposable wooden applicator sticks.  
The tube was capped using the screw cap and placed on a tube rocker, after which it was agitated for 
a minimum of 30 minutes at room temperature.  Room temperature was controlled by a central air-
conditioner and temperatures were digitally monitored to ensure a temperature between 15 oC and 
25 oC.  The tube rocker had a tilt angle range of 150 o to 210 o with a fixed speed of 24 rpm. 
After incubation on the rocker, samples were centrifuged for two minutes at 671 g. Sample caps were 
removed by placing a piece of paper towel over the cap and then gently releasing the cap. The use of 
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a paper towel to open the sample cap prevents the formation of a possible aerosol and subsequent 
contamination of samples. Once the sample was uncapped, any bubbles present were removed by 
using a disposable plastic pipette.  Thereafter samples were placed in the Panther sample racks with 
the barcode facing outward in order for the analyser to scan and record the serial number. 
2.2.3. Panther 
2.2.3.1. Analyser 
The Panther analyser is a fully automated nucleic acid testing platform used for the NAT screening of 
individual donations at WPBTS.   
Barcoded primary samples are loaded onto the Panther after which operator intervention is only 
required when the samples are removed. Wash Solution, Auto Detect 1, Auto Detect 2, Oil and Buffer 
for Deactivation (Universal Fluids) used by the analyser are labelled with RFID tags. Each component 
of the reagent and calibrator sets have unique barcodes that are read and recorded by the analyser 
providing complete traceability from sample to end result. 
 
2.2.3.2. Procleix Ultrio Elite Assay  
The Procleix Ultrio Elite (Grifols Diagnostic Solutions Inc, Spain) assay is a commercial nucleic acid 
test assay.  It is a multiplex assay based on the transcription-mediated amplification principle. It has 
been designed to detect Human Immunodeficiency virus type -1 and -2 viral RNA, Hepatitis B viral DNA 
and Hepatitis C viral RNA in serum and plasma specimens from humans.  The assay is a qualitative in 
vitro assay that is intended for blood screening of blood donors, of both live and cadaveric organ/tissue 
donors. Each result is validated by 1) calibration of the reagent set and 2) an internal control for which 
a result is generated simultaneously.  Only if the internal control has the expected result will the sample 
test result be deemed as valid. The internal control on each individual specimen confirms that no 
inhibition took place during the testing process. The calibrator set consists of a negative calibrator (run 
in triplicate), HIV Positive calibrator (run in duplicate), Hepatitis C Positive calibrator (run in duplicate), 
and a Hepatitis B calibrator (run in duplicate). Calibration for each reagent set is only valid for 24 hours, 
after which a new calibration has to be performed if test reagents are still available on the reagent set.  
 
Each test kit of 250 tests consists of: 
1.) Internal control reagent (IC) 
A hydroxyethyl-piperazineethane-sulfonic acid (HEPES) buffered solution containing 
detergent and an RNA transcript 
2.) Target capture reagent (TCR) 
A HEPES buffered solution containing detergent, capture oligonucleotides and 
magnetic microparticles 
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3.) Amplification reagents (AMP) 
Primers, Deoxynucleotides (dNTPs), Nucleoside triphosphates (NTPs) and co-factors 
in trisaminomethane (TRIS) buffered solution containing ProClin 300 as a preservative 
4.) Enzyme reagent  
MMLV reverse transcriptase and T7 RNA polymerase in HEPES/TRIS buffered 
solution containing 0.05% sodium azide as preservative 
5.) Probe reagent 
Chemiluminescent oligonucleotide probes in succinate buffered solution containing 
detergent 
6.) Selection Reagent 
Borate buffered solution containing a surfactant 
7.) Target enhancer reagent (TER) 
A concentrated solution of lithium hydroxide  
(Gen-Probe, 2015) 
2.2.3.3. Principles 
The Procleix Ultrio Elite assay process can be described in three main steps. 
1) Sample preparation by means of target capture resulting in isolation and purification of the viral 
nucleic acid within the sample. 
2) Amplification by means of transcription-mediated amplification resulting in the amplification of 
target nucleic acid sequences to produce multiple copies of RNA. 
3) Detection by means of hybridization protection assay whereby the amplified nucleic acid signal 
is detected using light-emitting nucleic acid probes. 
 
2.2.3.3.1.1. Sample preparation/Target Capture 
The Panther analyser takes a multi-tube unit (MTU) from the input queue and puts it in the sample 
dispense station. These MTU’s are 5 individual tubes that are moulded to form a single unit. In the 
sample dispense station, 400 µℓ working Target capture reagent (wTCR), which is the TCR and the IC 
reagent combined, containing the capture oligonucleotides, is added to each individual tube of the MTU. 
The capture oligonucleotides are short strands of ssDNA of specific base-pair sequence, i.e. the base 
pairs are complementary to the target viral sequence which targets a conserved region within each of 
the 3 viruses. Only one disposable pipette tip is used during the dispensing of wTCR into the five tubes 
of the MTU. 500 µℓ of the cooled sample is then added to an individual MTU tube using a disposable 
pipette tip for the addition of each sample. Thereafter wTCR and sample volume verification is 
performed to ensure that the exact amount of each was added to the tube. The sample is moved to the 
mixing station to ensure adequate mixing of the constituent fluids.  The MTU is then moved to the high-
temperature incubator.  The temperature within this incubator is 64 oC.  Detergent, within the TCR, lyses 
viral particles releasing nucleic acid which is then available for hybridization. At this stage, both target 
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sequences and the internal control RNA transcript are hybridized with matching oligonucleotides. Each 
of the oligonucleotides has a Poly-A tail, which allows for magnetic microparticles, with a poly-T tail, to 
bind to the oligo-target nucleic acid complexes when the sample is moved to the transition incubator. 
 
The MTU is then cooled in a chiller ramp where magnets pre-capture the magnetic beads to the side of 
the MTU. Once the magnetic bead has captured the targets the MTU move to the magnetic wash 
station. In the Mag wash station, a magnetic force is applied and residual fluids are aspirated.  The 
force is then removed and the wash solution is added, the sample is then mixed and the process 
repeated, resulting in purified target nucleic acid.  After completion of the wash, 200 µℓ of oil is dispensed 
to minimize evaporation during the rest of the assay process.  
 
2.2.3.3.1.2. Amplification 
After the completion of the mag wash and the addition of oil, the MTU is moved to the AMP load station 
where 75µℓ of amplification reagent is pipetted into each tube.  
The samples are then mixed and moved to the High-temperature incubator where the secondary 
structure of the RNA/DNA is disrupted and the primers anneal. The high temperature, 64oC, promotes 
binding the primers to the target nucleic acid in this assay as the oligonucleotides contained within this 
assay is designed to optimally bind at 64 oC.  Thereafter the MTU is moved for cooling to the transition 
incubator prior to enzyme reagent being added. The MTU is then moved to the AMP load station where 
25 µℓ Enzyme reagent is pipetted into the sample.  The MTU is mixed by means of an orbital mixer and 
transferred to the AMP/RT incubator for amplification at 42.7oC. The amplification process uses the 
transcription mediated amplification (TMA) principle.  The process initially differs for RNA and DNA 
target sequences but then follows the same loop after a dsDNA template which includes the T7 
promoter has been created. 
For RNA (HIV, HCV and IC): Primer 1, which includes a T7- promoter sequence, binds to the target 
allowing Reverse Transcriptase (RT) to create the first strand of cDNA,  resulting in an RNA: DNA 
complex. RT degrades the target RNA by means of its RNase H activity which results in single-
stranded cDNA. The second primer then binds to the cDNA allowing RT to create a second strand 
of cDNA. A dsDNA template including the T7-promoter sequence is produced.  
For DNA (HBV): The T7 primer and displacer primer bind to the target. Thereafter RT extends the 
displacer primer and T7 primer.  The Displacer primer elongation displaces the T7 DNA primer 
product, resulting in a T7 ssDNA. Primer 2 binds to the T7 DNA product and primes the second 
strand DNA. A dsDNA template including the T7-promoter sequence is now available for 
amplification. 
Both RNA and DNA processes result in ds DNA templates including the T7 promoter sequence, RNA 
polymerase initiates transcription of RNA from a DNA template resulting in 100 to 1000’s of RNA 
transcript. Primer 2 binds to RNA amplicon and creates the first strand of the new cDNA resulting in the 
completion of the RNA:DNA complex, after which the RT degrades the target RNA by means of its 
RNase H activity which results in a single-stranded cDNA. Primer 1 including the T7-promoter binds 
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and RT creates new double-stranded cDNA, the amplicon.  The amplicon then becomes the new 
template and the process repeats itself until the reagent supply is exhausted. The amplified product is 
called the amplicon which can now be hybridized with the labelled nucleic acid probe in the hybridization 
protection assay. 
2.2.3.3.1.3. Hybridization Protection Assay (HPA) 
During the HPA the single-stranded amplicon from TMA is hybridised with a single-stranded nucleic 
acid probe that is labelled with an acridinium ester molecule. The sequence of the labelled nucleic acid 
probe complements the target sequence. The analyser moves the MTU to the HPA load station. 100 µℓ 
of probe reagent is dispensed into the tube and the tube content is mixed. Since the labelled probe 
complements the target sequence, it will bind if the target sequence is present. The MTU is then moved 
to the high-temperature incubator for hybridization. Once hybridization is complete the MTU is moved 
to the HPA load station where 250 µℓ Selection reagent is added, and then to the high-temperature 
incubator for the selection process.  During the selection process, the un-hybridized AE is hydrolysed 
from any unbound probe as these AE are not “protected” within a double-stranded helix.  As soon as 
the selection process has been completed the system dispenses Auto detect 1 and Auto detect 2 which 
react with the AE, emitting photons.  The light-signal is read by the luminometer if a light signal is 
present.  The sample results are validated by the dual kinetic assay.  This technology allows the 
analyser to differentiate between kinetic profiles of the labelled probes. The IC, for example, is labelled 
with very rapid kinetics producing a rapid emission of light called a “flasher” whereas the sample kinetic 
profile is much slower thus producing relatively slower emission of light called a glower.  A negative 
sample result will have a “glower” reading, while a reactive sample will have both a “flasher” and a 
“glower” reading. 
2.2.3.4. Interpretation of results 
Panther results are reported as sample to cut-off (S/CO) values and all calculations are performed by 
the software on the Panther analyser.  For each analyte two cut-offs are determined during calibration, 
one for the analyte (produced by the glower) and one for the internal control of the sample (flasher).  
The analyte value is reported in relative light units (RLU) which are then converted to S/CO based on 
the cut-offs determined by calibration. An S/CO value equal to or greater than 1 is considered as 
reactive. 
 
2.2.3.5. Confirmation of reactive results 
2.2.3.5.1. Cohort A 
Once a DBS sample result was found to be initially reactive, the DBS sample was retested in duplicate.  
If only 1 of the 3 results were found to be reactive the sample was considered as Initial-Reactive/Non-
Repeat-Reactive (IR/NRR).  No further testing was performed, however, for statistical calculations, 
these results were interpreted as negative.  However, if two or all three results were found to be reactive, 
the sample was considered reactive and discriminatory (dHXV) testing was performed to identify the 
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virus present in the donor’s blood sample. This testing algorithm is similar to the testing algorithm used 
routinely in WPBTS virology laboratory, a simplified version of which is illustrated in Figure 2.2.   If the 
results obtained on the DPS/DBS and the original sample results were discrepant a fresh spot would 
have to be made, however, if the test result of the fresh spot correlates with the original sample’s results 
no further testing would have been required.  The interpretation of Cohort A results is also illustrated in 
Figure 2.3. 
 
2.2.3.5.2. Cohort B 
Plasma samples were confirmed reactive by routine NAT testing and re-testing of the plasma bag. 
DBS/DPS samples were considered reactive if the sample was initially reactive.  Discriminatory (dHXV) 
testing was performed on these samples, where volume allowed, to determine the virus present. The 
interpretation of Cohort B results is also illustrated in Figure 2.3. 
. 
 
2.2.3.6. Data processing and storage 
De-identified DPS and DBS sample results from the Panthers were transmitted to eL@bs (PANTHER 
middleware) which served as a database for all DBS/DPS and NAT test results.  Results could be 
distinguished based on the prefixes. The original plasma sample was denoted with an N- prefix, the 
DBS sample with a B-, and the DPS sample with a P-.   
 
2.2.4. Statistical analysis 
Statistical analysis was performed to compare the results from the original plasma sample versus the 
DPS/DBS sample.   
Analysis of the 3 sets of results included: 
 Sensitivity/Specificity  
 Positive and negative predictive values (false positive/false negative) 
 Statistical significance of any differences measured using concordance analysis which includes: 
- Cohen’s Kappa coefficient (Stata version 15) 
- Or Bland Altman where relevant (Stata version 15) 
 Calculating the lower level of detection for each virus 
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CHAPTER THREE 
3. RESULTS 
 
In this study, two different cohorts were used to evaluate the suitability of DBS and DPS as samples for 
routine screening of blood.  Cohort A consisted of New Donors (ND) who tested negative for HIV, HBV, 
and HCV genome on the Panther Ultrio Elite during routine screening performed on a plasma sample.  
Cohort B consisted of samples that had been confirmed positive for at least one of the HIV, HBV, or 
HCV viruses. 
 
3.1. COHORT A 
Nine hundred screening-negative DBS and DPS samples were tested. The results of these tests are 
summarized in  
Table 3.1. 
Table 3.1. Ultrio Elite results for DBS/DPS samples prepared from 900 screening negative 
samples.  
 
Of the 900 known non-reactive DBS samples tested on Ultrio Elite, two tested initially reactive.  When 
retested, as per algorithm, these two samples tested non-reactive. These two samples were therefore 
re-classified as non-reactive in accordance with the algorithm used in this study. The sample to cut-off 
(S/CO) values of the repeat tests were used for further calculations. In addition, with the inclusion of the 
repeat tests, all Cohort A DBS samples were regarded as non-reactive resulting in a 100% specificity 
(95% confidence limit (CL): 99.59% to 100.00%) for the Ultrio Elite.  
Five of the 900 DBS samples were found initially invalid due to the internal control (IC) failing.  On 
repeat testing valid non-reactive results (i.e. the internal controls did not fail) were obtained on these 
five samples. 
 DBS DPS 
Number of samples found non-reactive 898/900 900/900 
Number of samples found initially reactive 2/900 0/900 
Number of samples found repeat reactive 0/2 N/A 
Number of samples found initially invalid 5/900 0/900 
Number of initially invalid samples found non-reactive on repeat testing. 5/5 N/A 
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All 900 known non-reactive DPS samples tested on Ultrio Elite were found to be non-reactive, resulting 
in a 100% specificity (95% CL: 99.59% to 100.00%). 
3.1.1. S/CO values 
On average, DBS samples had a higher and a wider distribution of S/CO values than both DPS and 
plasma samples. Comparing the mean S/CO values for the plasma and DBS samples a bias (-0.117) 
existed and results were not all within the 95% limits of agreement. On the other hand, when comparing 
the mean S/CO values for the plasma and DPS samples no bias (0.00) existed and most results were 
within the 95% limits of agreement.  In addition, the difference between the mean S/CO values of DPS 
and DBS samples was significant.  These results are illustrated in Figure 3.1, Figure 3.2, and Figure 
3.3 
 
Figure 3.1. Distribution of S/CO values of negative plasma, DBS, and DPS samples tested. The 
mean and p-values are included.  
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Figure 3.2.  The Bland Altman chart plotting the difference between the plasma S/CO values and 
DBS S/CO values versus the mean of the plasma S/CO AND DBS S/CO values. 
 
Figure 3.3.  The Bland Altman chart plotting the difference between the plasma S/CO values and 
DPS S/CO values versus the mean of the plasma S/CO and DPS S/CO values.  
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3.1.2. Negative Predictive Values 
Negative predictive values (NPV) for both DBS and DPS samples were 100% when calculated based 
on Cohort A. However, to be meaningful they needed to be re-calculated taking real-life donor 
prevalences in our region into account. The average prevalence of Hepatitis B, Hepatitis C, and HIV 
combined within the WPBTS blood donor base has been 0.038 for the past 5 years (2013 - 2017). This 
value is based on viral infection defined as a donor presenting 
1. both NAT and serologically reactive for the appropriate virus (concordant),  
2. NAT and discriminatory test reactive for the appropriate virus (NAT yield),  
3. and serologically reactive (serological yield), with confirmatory serological test reactive and 
Western blot or immunoblot reactive.   
In the last 5 years most reactive cases results were concordant (90%), followed by NAT yields (7%), 
and lastly serological yields (3%). The NAT yield consisted of window period (WP) samples (HIV and 
HBV) and occult HBV infections. Serological yields consisted of HIV elite controllers/donors on 
antiretroviral therapy as well as chronic HBV infections.  
Using the NPV formula based on Bayes’ theorem, 
𝑁𝑃𝑉 =
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 ×  ( 1 − 𝑃𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)
(1 − 𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦) × 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 + 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 × (1 − 𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒)
 
and using the WPBTS donor average prevalence, the NPV would be 99.99 % for both DBS and DPS.  
3.2. COHORT B 
 
3.2.1. Contamination Panel 
 
The contamination panel used consisted of 40 well characterized donor samples, 28 of which were 
known positive plasma samples and twelve that were known negative plasma samples. Contamination 
panel results are summarized in Addendum B.  No contamination was observed. All negative samples 
tested negative as expected; however, three positive samples had false negative test results. 
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3.2.2. Donor samples 
A hundred DBS and DPS samples were prepared from confirmed reactive donor samples from WPBTS.   
 
3.2.2.1. HIV 
Forty confirmed HIV-1 reactive samples were available for testing as DBS and DPS samples. Ten of 
these were available as plasma samples only and 30 as whole blood samples. Hence only 30 DBS 
samples could be prepared and tested while 40 DPS samples were available. The HIV test results of 
these samples are shown in Table 3.2  Note that the DBS false non-reactive sample was not the same 
sample as the DPS sample found to be false non-reactive. The HIV-1 sensitivity on plasma samples 
claimed for the Ultrio Elite assay is 100% (95% CL:98.3% to 100%) (Gen-Probe, 2015). 
 
Table 3.2. : Summary of the 30 DBS and 40 DPS test results for the HIV reactive donor samples 
tested 
 
 
Of the known HIV reactive samples 30 were tested as DBS. Twenty nine DBS samples were found to 
be reactive and one non-reactive, resulting in a HIV sensitivity for the Ultrio Elite using DBS samples of 
96.67% (95% CL 82.87% to 99.92%). All 30 samples were also tested with dHIV, including the one that 
tested negative on the Ultrio Elite assay (outside of this study setting this sample would not have been 
included for the dHIV testing). All 30 samples tested reactive on dHIV.   
 
Of the known HIV reactive samples 40 were tested as DPS. Thirty nine DPS samples were found to be 
reactive and one non-reactive, resulting in a HIV sensitivity for the Ultrio Elite using DPS samples of 
97.50% (95% CL: 86.84% to 99.94%).  
One sample, which was prepared as both DBS and DPS, was a window period sample. The window 
period sample had an HIV viral load of 45356 cps/mℓ but no detectable antibodies on the index sample. 
This sample was found to be reactive on both DBS and DPS. Approximately one month later, a follow-
up sample from the donor showed they had developed Anti-HIV.  
  
Sample type 
Matched samples Additional samples 
DBS DPS DPS 
Number of samples that tested reactive on Ultrio 
Elite 
29/30 30/30 9/10 
Number of samples that tested reactive on  
discriminatory assay for HIV-1/2 (dHIV) 
29/29 29/29 9/10 
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3.2.2.2. HBV 
 
Fifty confirmed HBV reactive samples were available for testing as DBS and DPS. All 50 of these were 
available as plasma samples, but only 33 were available as whole blood samples. Hence, only 33 DBS 
samples could be prepared and tested, compared to the 50 DPS samples which could be prepared and 
tested. The HBV test results of these samples are shown in Table 3.3 
 
 The HBV sensitivity on plasma samples claimed for the Ultrio Elite assay is 100% 
(95% CL: 98.3% to 100%) (Gen-Probe, 2015). 
 
Table 3.3. Summary of the 33 DBS and 50 DPS test results of HBV reactive donor samples . 
Thirty-three known HBV reactive DBS samples were tested on Ultrio Elite, 19 of which were found to 
be reactive and 14 non-reactive. These results indicate a HBV sensitivity for the Ultrio Elite using DBS 
samples of 57.58% (95% CL: 39.22% to 74.52%). The 19 reactive DBS samples were further tested on 
the dHBV and 18 tested reactive for dHBV.   
Fifty known HBV reactive DPS samples were tested on Ultrio Elite, 29 of which tested reactive and 21 
non-reactive. These results indicate a HBV sensitivity for the Ultrio Elite using DPS samples of 58.00% 
(95% CL: 43.21% to 71.81%). The 29 reactive DPS samples were further tested on the dHBV.  Of the 
samples tested on the dHBV, 25 were found to be reactive and 4 non-reactive.   
Both the DBS and DPS samples tested on Ultrio Elite showed a statistically significant reduction in 
sensitivity compared to the plasma samples. Below is a table (Table 3.4) showing the S/CO values for 
each of the tests from the same sample source, with reference to any additional confirmatory tests that 
were performed. 
 
  
Sample type 
Matched samples Additional samples 
DBS DPS DPS 
Number of samples that tested reactive on Ultrio 
Elite 
19/33 19/33 10/17 
Number of samples that tested reactive on  
discriminatory Assay for HBV (dHBV) 
18/19 19/19 6/10 
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Table 3.4. S/CO values for DBS and DPS samples that tested non-reactive for well characterised 
HBV reactive samples. 
 
Serial 
Number 
Plasma 
S/CO 
DBS 
S/CO 
DPS 
S/CO 
HBsAg 
Serology 
S/CO 
Supplementary test results 
2 7.14 0.06 0.05 9.28 Confirmed Reactive 
3 13.23 0.14 0.04 42.2 Confirmed Reactive 
4 14.81 0.17 0.2 0.773 Confirmed Reactive 
8 13.64 0.12 0.05 3.7 Confirmed Reactive 
9 14.09 0.07 0.12 3856 Viral Load Detected LDL <116 cps/mL 
18 14.97 0.07 0.12 30.58 Confirmed Reactive 
20 13.06 0.08 0.04 6834 Confirmed Reactive 
21 13.45 0.13 0.02 7427 Confirmed Reactive 
23 13.20 0.26 0.1 1587 Viral Load Detected LDL <116 cps/mL 
25 9.36 0.1 0.06 0.572 Confirmed Reactive 
28 13.29 0.12 0.34 0.574 Confirmed Reactive 
29 14.78 0.09 0.11 2355 Confirmed Reactive 
32 14.15 0.07 0.05 3608 Confirmed Reactive 
33 13.60 0.12 0.04 4879 Confirmed Reactive 
11 14.22 13.24 0.05 2236 Confirmed Reactive 
36 13.66 NT 0.12 7014 Viral Load Detected LDL <116 cps/mL 
45 13.74 NT 0.1 0.593 Confirmed Reactive 
46 13.38 NT 0.13 1255 Viral load 361 cps/mL 
48 14.11 NT 0.13 0.538 Confirmed Reactive 
49 14.65 NT 0.1 0.545 Confirmed Reactive 
50 14.16 NT 0.1 0.593 Confirmed Reactive 
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3.2.2.3. HCV 
Ten known HCV reactive samples were available for testing. All ten samples were reactive for both anti-
HCV and NAT. No window period samples were available since the WPBTS donor population has a 
very low HCV prevalence (0.03%) and has not seen a donor during the HCV window period since the 
start of NAT testing in 2005. The HCV test results of these samples are shown in Table 3.5. The HCV 
sensitivity on plasma samples claimed for the Ultrio Elite assay is 100% (95% CL: 98.2% to 100%). 
 
Table 3.5. Summary of the two DBS and ten DPS test results of HCV reactive donor samples 
Two known HCV reactive DBS samples were tested on Ultrio Elite and both were found to be reactive. 
This small sample size resulted in an HCV sensitivity for the Ultrio Elite using DBS samples of 100% 
(95% CL: 15.81% to 100.00%).  Both DBS samples were as per algorithm further tested on dHCV and 
found to be positive.  
 
Ten known HCV reactive DPS samples were tested on Ultrio Elite were all found to be reactive. The 
resulting HCV sensitivity for the Ultrio Elite using DPS samples was calculated to be 100% (95% CL: 
69.15% to 100.00%).   Of the 10 DPS reactive samples, 9 were further tested on the dHCV (the tenth 
DPS sample was excluded due to insufficient sample volume) and found to be reactive.    
 
3.2.3. Procured samples 
 
Three reactive validation plasma samples, with known viral loads, were procured for HIV-1, HBV, and 
HCV respectively from the National Serology Reference laboratory (Fitzroy, Australia). The samples 
were serially diluted with saline until non-reactive values were obtained.  The objective of the dilutions 
were to determine analytical sensitivity and to calculate the lowest level of detection (LOD) for each 
virus using Ultrio Elite and DPS as sample type. A further objective was to test for stability of the DPS 
samples after three weeks of storage. 
 
  
Sample type 
Matched samples 
Additional 
samples 
DBS DPS DPS 
Number of samples that tested reactive on 
Ultrio Elite 
2/2 2/2 8/8 
Number of samples that tested reactive on  
Discriminatory Assay for HCV (dHCV) 
2/2 2/2 7/7 
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3.2.3.1. Results of samples tested within a week of preparing the sample on the DPS cards.  
 
3.2.3.1.1. HIV 
The reference HIV viral load results supplied by the National Serological Reference Laboratory (NRL) 
were 101 000, 193 000, 326 000 cps/mℓ for the three procured samples respectively. Addendum D and 
E give an overview of the S/CO results obtained for each dilution. The dilution factor was calculated by 
using the buffer volume divided by the amount of plasma that was added to the DPS.  This factor can 
be used to calculate the viral load present in the DPS eluted sample. 
When using the Ultrio Elite assay the lowest S/CO that would be interpreted by Panther as reactive is 
1.00.  Lowest level of detection (LOD) calculations were based on the linear regression formula derived 
from the scatter plot of the serial dilutions. The best fit linear equation was determined to be, 
𝑦 = 4.3725𝑥 − 9.745 
where x represents the log of the viral load and y represents the S/CO value. Therefore, when the S/CO 
value is 1.00 the linear relationship determines that the log of the viral load will be 2.09 cps/mℓ. We thus 
conclude that theoretically for a DPS sample the assay’s LOD is 124.11 cps/mℓ present in the plasma 
sample. This means that the LOD for viral load within the eluted DPS sample is theoretically 
6.21 cps/mℓ.   
The lowest viral load that tested reactive using a DPS sample was 376.95 cps/mℓ in the plasma sample 
with only 18.85 cps/mℓ present in the elution that was tested.  The levels of detection calculated in this 
study must be used with caution since these calculations were based on 30 data points derived from 
dilutions from only three unique samples, rather than from a comprehensive study involving probit 
analysis of multiple repeats at various viral loads. 
 
3.2.3.1.2. HBV 
The reference HBV viral load results supplied by the National Serological Reference Laboratory (NRL) 
were 135 520 000, 110 320 000, 868 000 000 cps/mℓ for the three procured samples respectively. 
Addendum F and G give an overview of the S/CO results obtained for each dilution.  Results of the 
doubling serial dilutions are stipulated in Addendum F, however, due to the fact that no non-reactive 
S/CO was reached, new serial dilutions were made, using ten-fold dilutions. Results for the ten-fold 
serial dilutions are listed in Addendum G.  Samples were tested in duplicate.  Addendum H illustrates 
the results of both the HBV positive two-fold dilutions as well as the ten-fold dilutions.  
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Lowest level of detection (LOD) calculations were based on the linear regression formula derived from 
the scatter plot of the serial dilutions. The best fit linear equation was determined to be, 
   𝑦 = 2.5429𝑥 − 3.6656 
where x represents the log of the viral load and y represents the S/CO value. Therefore, when the S/CO 
value is 1.00 the linear relationship determines that the log of the viral load will be 1.83 cps/mℓ. We thus 
conclude that theoretically for a DPS sample the assay’s LOD is 68.32 cps/mℓ present in the plasma 
sample. This means that the LOD for viral load within the eluted DPS sample is theoretically 3.42cps/mℓ.  
These LOD were calculated using linear regression and are based on 48 data points derived from 
dilutions of 3 different samples. 
 
3.2.3.1.3. HCV 
The reference HIV viral load results supplied by the National Serological Reference Laboratory (NRL) 
were 1067800, 4598000, 2128000 cps/mℓ for the three procured samples respectively. Addendum I 
and J give an overview of the S/CO results obtained for each dilution. 
LOD calculations were based on the linear regression formula derived from the scatter plot of the serial 
dilutions. The best fit linear equation was determined to be, 
y = 3.663x − 12.63 
where x represents the log of the viral load and y represents the S/CO value. Therefore, when the S/CO 
value is 1.00 the linear relationship determines that the log of the viral load will be 3.04 cps/mℓ. We thus 
conclude that theoretically for a DPS sample the assay’s LOD is 1096.48 cps/mℓ present in the plasma 
sample. This means that the LOD for viral load within the eluted DPS sample is theoretically 
54.82 cps/mℓ. 
The Ultrio Elite package insert claims a detection limit (95% confidence limit) of 11.4 cps/mℓ. If detection 
limit is applied to the elution (using a dilution factor of 20) this can be converted into an HCV viral load 
of 228 cps/mℓ in the plasma sample prior to the preparation of the DBS/DPS. These LOD were 
calculated using linear regression that is based on 30 data points derived from dilutions of 3 different 
samples. 
 
3.2.3.2. Result samples tested 3 weeks after spotting the sample on the DPS card. 
As previously stated, one of the objectives of this study was to determine stability of DPS samples after 
three weeks of storage. In aid of this, a second undiluted HIV, HBV & HCV DPS card was prepared 
simultaneously as the first, but only tested 3 weeks later.  The DPS card was kept at room temperature 
on the bench during these weeks.   
Table 3.6Table 3.6 below the S/CO values obtained from the first test, done within one week after the 
DPS sample preparation and referred to as Test 1,  and the second test, done after three weeks of 
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storage and referred to as Test 2, are listed.  
 
Table 3.6.  Comparison of S/CO values obtained for the DPS samples within one week (test 1) 
and three weeks (test 2) after preparation 
 S/CO of Test 1 S/CO of Test 2 
HIV 9.88 10.37 
HBV 14.78 14.56 
HCV 9.69 9.58 
 
Comparing the S/CO values of Test 1 and Test 2, a 99.3% correlation was calculated, with an average 
S/CO difference between the two test sample sets of 0.02. Furthermore, the S/CO values for Test 1 
and Test 2 were found not to be statistically significant (Student’s t-test, p> 0.05). 
The stability results within this study must be used with caution since these were based on three sample 
sets.   
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3.3. SUMMARY 
In Table 3.7 below, the specificity, sensitivity, NPV, PPV, and accuracy results obtained in this study for 
each cohort, and the combined cohorts where applicable, are tabulated to provide a summarised 
overview. 
 
Table 3.7.  Summary of specificity, sensitivity, NPV, PPV, and accuracy results for cohorts A and 
B 
 DBS DPS 
 n= % n= % 
Specificity     
Cohort A 900 100% 900 100% 
Sensitivity     
Cohort B     
HIV 30 96.67% 40 97.50% 
HBV 33 57.58 % 50 58 % 
HCV 2 100 % 10 100 % 
NPV     
Cohort A  900 100 % 900 100 % 
     
HIV 30 99.99 % 40 99.99 % 
HBV 33 98.46 % 50 97.72 % 
HCV 2 100 % 10 100 % 
Total 65 98.36 % 100 97.61 % 
Overall NPV 
Taking WPBTS donor prevalence into account 
965 99.99% 1000 99.99% 
PPV     
Cohort B     
HIV 
WPBTS donor prevalence 0.041% 
30 96.67% 40 97.50% 
HBV 
WPBTS donor prevalence 0.060%   
33 57.58 % 50 58 % 
HCV 
WPBTS donor prevalence 0.03%  
2 100 % 10 100 % 
Total 65 76.92% 100 78.00% 
Overall PPV 
Taking WPBTS donor prevalence into account 
965 99.99 % 1000 99.99 % 
Overall     
Accuracy 965 98.45% 1000 97.80% 
Cohen’s Kappa coefficient  965 0.8615  1000 0.8645  
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CHAPTER FOUR 
4. DISCUSSION 
The collection of blood donations varies tremendously from high-income to low-income countries. Low-
income countries are often unable to meet the transfusion demand (WHO, UNICEF and UNAIDS, 
2011).  Of the blood donations collected in SSA only 85.5% (Tapko, Toure and Sambo, 2014) of these 
are screened, by means of serological, NAT, and/or rapid diagnostic testing (RDT), for transfusion 
transmitted diseases (TTDs). 
 
4.1 BLOOD SCREENING 
Ideally all blood donations should be screened for TTD.  At a minimum, these tests should include Anti-
HIV, HBsAg, Anti-HCV and syphilis testing.  Where feasible, additional markers should be added, 
tailored to the country and their donor population's epidemiological situation. In particular, the nucleic 
acid test (NAT) for HIV, HBV and/or HCV should be included where possible. (World Health 
Organization, 2010) 
 
4.2 DBS/DPS 
DNA extraction from blood spots dried on filter paper was first described in 1987 (McCabe et al., 1987).  
The first HIV-RNA viral extraction from a DPS sample was described in 2003 (Brambilla et al., 2003).  
Since these initial descriptions many publications evaluating the stability, suitability, reduction in cost, 
and ease of use of DBS/DPS samples for NAT have been published. Results from these publications 
indicate that using DBS/DPS samples for screening and testing is comparable to using traditional 
plasma samples.   
DBS samples are being used successfully in the early infant diagnosis (EID) programs for HIV by means 
of PCR testing. This advance in EID is especially relevant SSA where cold chain management of 
sample shipment and sample storage are challenging, and has enabled millions of children to be 
screened for HIV-RNA(Essajee, 2013). This example of a successful, cost effective intervention using 
DBS is a motivator to do more studies for the feasibility of applying DBS/DPS in order to improve access 
to medical services with SSA. 
 
4.3 FINDINGS 
During this study, 900 non-reactive and 100 reactive plasma samples were prepared as DBS and DPS 
samples.  These samples were tested on the Panther analyser using the Ultrio Elite assay. The results 
were compared to the standard routine test results to determine sensitivity, specificity, and utility of 
DBS- and DPS-testing in a resource constraint blood transfusion setting.  
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Sensitivity is defined as the “diagnostic sensitivity; the conditional probability that a person having a 
disease will be correctly identified by a clinical test, i.e., the number of true positive results divided by 
the total with the disease (which is the sum of the numbers of true positive plus false negative results). 
See also specificity.”  (Miller-Keane Encyclopaedia and Dictionary of Medicine, Nursing, and Allied 
Health. 7th edn, 2003).  
Specificity is defined as “the probability that a person not having a disease will be correctly identified by 
a clinical test, i.e., the number of true negative results divided by the total number of all those without 
the disease (which is the sum of the number of true negative plus false positive results).” (Miller-Keane 
Encyclopaedia and Dictionary of Medicine, Nursing, and Allied Health. 7th edn, 2003) 
Overall screening sensitivity was found to be reduced when using both DBS and DPS samples. 
Screening specificity was comparable to routine screening but additional result interference was 
observed with the DBS samples. 
 
4.3.1 Sensitivity 
The sensitivity of a screening assay is one of the most important considerations in a blood transfusion 
setting. Acquiring a TTD could result in disease or even death of the transfusion recipient.  Furthermore, 
it is important to identify a donor as being infected with a virus.  The WHO Regional office for Africa 
compiled a strategy in 2001 to improve blood safety by improving both the quality and adequacy of 
blood products (Tapko, Toure and Sambo, 2014). One of the main objectives was a reduction of 
transfusion-acquired infections. Based on an estimated 2 million donations given annually Jayaraman 
et al. estimate that 15 600 TTD infections (13% HIV, 55% HBV, and 32% HCV) are acquired in SSA 
every year. If the WHO target of collecting 6.65 million donations annually in SSA was met, 51 580 TTD 
infections would be acquired annually. These would include, 28 595 cases of HBV, 16 625 cases of 
HCV and 6 650 cases of HIV (Jayaraman et al., 2010). 
The WHO recommends that all blood screening assays, whether serological or NAT, should have a 
minimum sensitivity and specificity of 99.5 %, and that test sensitivity and specificity should be as high 
as possible (World Health Organization, 2010).  The reduction of the risk of an infectious unit entering 
the blood supply is largely determined by the sensitivity of the screening assays used.  If assays with a 
99.5% sensitivity were used, the 51 580 TTD infections annually acquired could be reduced to 33 250, 
therefore if the 6.65 million donation target were met, 6.62 million of the donations would be free of the 
TTD’s tested for.  
 
4.3.1.1 HIV 
HIV is a leading cause of death and disease in SSA (Wang et al., 2016). The burden of disease in SSA 
is disproportional, with only 14% of the world population residing in SSA it carries more than 65% 
(Tapko, Toure and Sambo, 2014; Kharsany and Karim, 2016) of the global HIV burden. The risk of 
acquiring an HIV infection from a transfusion in SSA is calculated to be 1 000 for every 1 000 000 
donations collected (Jayaraman et al., 2010).  At WPBTS 100% of donated blood is screened for TTDs, 
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including testing for HIV serologically and by NAT. At WPBTS the overall TTD residual risk is calculated 
to be 1.31 per 1 000 000 donations, which is significantly lower than the SSA risk.   
An HIV free generation can only be realised with the prevention of HIV transmission. Unsafe blood 
contributes to the transmission of HIV. Unsafe blood, due either to not being screened or being 
screened with low sensitivity antibody-only assays, is projected to contribute to 2 000 infections within 
SSA annually (Jayaraman et al., 2010).  
In counties where the prevalence of HIV is high, the number of incident infections is high.  Therefore 
the risk of blood donations taking place during the window period is higher in high that in low HIV 
prevalence setting. El Ekaiby et al. concluded that the introduction of NAT would be of greater relative 
value in higher TTD  prevalence settings (El Ekiaby, Lelie and Allain, 2010). 
Within this study, one window period sample was tested using both DBS and DPS, and in both cases 
the samples had reactive results. This indicated that NAT using DBS or DPS samples would have 
identified the donor as being HIV positive, even though serological tests were negative. 
The sensitivity of Ultrio Elite for plasma is claimed to be 100% (95% CL: 98.3% - 100%) (Gen-Probe, 
2015). The HIV-1 sensitivity of Ultrio Elite using DBS and DPS was found to be 96.67 % and 97.50 %, 
respectively.  DPS has a slightly higher sensitivity than DBS, this is most likely due to the increased 
plasma content in the DPS sample as compared to the DBS sample.    
For HIV testing using DPS, linear regression suggested a lowest level of detection (LOD) of 
24.11 cps/mℓ. When comparing our LOD with the LOD found in Mössner et al’s study, our LOD is lower 
than their reported LOD of 500 cps/mℓ. Mössner et al’s study also used the Ultrio Elite assay, however 
they used DBS as their sample type (Mössner et al., 2016).     
The infectious dose where 50% of the population (ID50) would acquire HIV in a blood transfusion setting 
is calculated to be 632 copies (Weusten et al., 2011; Vermeulen et al., 2013) contained within the 20 mℓ 
plasma found in a red blood cell concentrate (RCC) unit. This translates to the blood donor having a 
viral load of c.31.6 cps/mℓ to be infectious.  Each type of blood product contains different volumes of 
plasma. The higher the plasma content of the product the higher the potential absolute viral count in 
the product. Conversely, if the plasma content is very low the potential absolute viral count will be very 
low.  Therefore as the plasma content differs in the products, different viral loads within the donor could 
result in an infection.   
Within this study, the lowest viral load that tested reactive on a DPS sample was 380.18 cps/mℓ 
(2.58 log) which is much higher than the calculated detectable viral load of 24.11 cps/mℓ. The 
discrepancy could have been due to our small sample size and the possibility of a non-linear detection 
at low viral loads. If the calculated LOD were verified, using DPS samples for testing would prevent HIV 
transmission as it is lower than the ID50 of HIV which is 31.6 cps/mℓ. Comparing the viral load detection 
sensitivity for DPS and plasma samples, we found a reduction in sensitivity for HIV using DPS samples 
of approximately 1 log10 in viral load compared to the assay claims on plasma samples. 
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4.3.1.2 HBV 
NAT was originally introduced as an additional safeguard in addition to serological screening. Originally 
it was thought that NAT testing would be most beneficial in the fight against HIV, since then it has been 
proven most useful in identifying occult Hepatitis B infection (OBI) cases (El Ekiaby, Lelie and Allain, 
2010). To illustrate this, from 2011 up to and including 2017, 34 HIV NAT yield (i.e. HIV antibody 
negative) donations were received out of 1 113 916 donations, in comparison, a staggering 79 HBV 
NAT yield (i.e. Hepatitis B surface antigen negative) donations were received. Bearing in mind that an 
average of three different blood products is made from each donation, 102 potential HIV transmissions 
have been prevented compared to an astounding 237 potential HBV transmissions.  
The use of DBS/DPS samples affected performance of HBV NAT adversely.  The HBV reactive portion 
of Cohort B re-tested using DBS/DPS in this study had the lowest sensitivity. The 1 log10 reduction or 
more in sensitivity when using DBS/DPS instead of plasma samples with regard to HBV has been 
documented in a number of other studies (Jardi et al., 2004; Lira et al., 2009; Stene-Johansen et al., 
2016)The HBV sensitivity for Ultrio Elite using DBS and DPS was 57.58 % and 58.00 % respectively, 
much lower than the 100% HBV sensitivity for plasma samples stated in the package insert (Gen-Probe, 
2015). The determined sensitivities were also lower than the universal recommended sensitivity of 
99.5% for all TTD assays (World Health Organization, 2010).  DPS had a slightly higher sensitivity to 
HBV than DBS, this was most likely due to the higher plasma content in the DPS sample as compared 
to the DBS sample. 
The failure of detection in almost half of the DBS/DPS samples that should have been positive for HBV 
could be due to two reasons. 
1. The viral loads in the samples tested were so low that they were undetectable in the eluate.  
The eluate comprised of 100µℓ of dried DBS/DPS sample which was eluted into a 2mℓ of 
buffer, thus the volume of plasma in the eluate was at least 20 fold lower than a traditional 
plasma sample. When the viral load is very low in the donor sample, the discrepancy between 
the HBV sensitivities of plasma and DBS/DPS are enhanced. To test this hypothesis four 
plasma samples from the original reactive Cohort B were sent for viral load testing, the viral 
load for three of the samples were found to be less than 116 cps/mℓ (unquantifiable) and the 
fourth sample 361 cps/mℓ.  This observation is probably due to the nature of the HBV infection 
in the donors, there is a strong possibility the donors had occult HBV since most of the NAT 
yield donors within WPBTS were Anti-HBc positive.  
 
2. The Ultrio Elite assay may not be as effective at denaturing the double stranded DNA as 
required, thus there was a reduction in the release of viral genomic DNA (Grabarczyk et al., 
2015).  The prominently reduced sensitivity was only observed for HBV which supports the 
ineffective DNA denaturing hypothesis since HBV is the only DNA virus of the three viral 
genomes tested. 
Stellenbosch University  https://scholar.sun.ac.za
45 
 
The ID50 has been calculated to be 3.16 virions (Weusten et al., 2011) within a RCC for HBV by 
mathematical modelling. HBV does, however, have 2 different ID50 levels which are determined by the 
stage of the infection in the donor. The first ID50 is 3.2 virions during the initial window period (WP) of 
the HBV infection where the viral ramp-up is high (Vermeulen et al., 2014). The second ID50  is during 
the Anti-HBc positive WP where the viral replication is reduced, and the ID50 is 100 fold lower at 316 
virions.  
Within this study the lowest HBV viral load that tested reactive using a DPS sample was 11032 cps/mℓ 
in the plasma sample (552 cps/mℓ present in the eluate). Only one sample with a higher viral load 
(13552 cps/mℓ) tested non-reactive.  Mathematical modelling (linear regression) does, however, 
suggest that the Ultrio Elite should theoretically be able to detect HBV at levels as low as 68.32 cps/mℓ 
which is below the ID50 for the Anti-HBc positive window period phase of the HBV.  The lowest viral 
loads that were found reactive were far above the infectious dose level for HBV therefore transmission 
would not be prevented based on DPS NAT only.  
 
4.3.1.3 HCV 
The prevalence of HCV within the WPBTS is very low, an average of 0.0030% of donations presented 
with concordant HCV in the last 5 years. For this reason only ten HCV reactive samples were available 
for testing on DPS and only two on DBS.  WPBTS has not had an HCV window period donor since the 
implementation of NAT testing in October 2005. 
The sensitivity for Ultrio Elite using DBS/DPS was 100% which matched the sensitivity claimed for Ultrio 
Elite on plasma samples (Gen-Probe, 2015).  These levels are above the recommended 99.5% 
sensitivity levels for all TTD assays (World Health Organization, 2010). These result needs to be 
considered in the context of a very small sample size. 
As with HBV, HCV has two ID50 levels for different infection stages.  The first ID50 is calculated to be 
3.16 cps/mℓ in RNA-positive anti-HCV negative donors, and the second ID50 is calculated to be 
316 cps/mℓ when anti-HCV are present in the donor (Bruhn et al., 2015; El Ekiaby et al., 2015). The 
neutralizing effect of the HCV antibodies afford some degree of protection to the recipients.  
In this study, the lowest viral load that tested reactive using a DPS sample /mℓ in the plasma sample 
with only 208 cps/mℓ present in the elution that was tested. This is lower than the calculated LOD for 
HCV based on linear regression.  Not all low viral load samples tested reactive, and some samples with 
viral loads higher than 792 cps/mℓ tested non-reactive. This could be due to the fact to the very low viral 
load present in the dilution as a result of the large dilution factor (20) which results from adding two 
50 µℓ samples to 2 000 µℓ of buffer. 
Within this study the lowest HCV viral load that tested reactive using a DPS sample was 4176 cps/mℓ 
in the plasma sample (208 cps/mℓ present in the eluate). Mathematical modelling (linear regression) 
does, however, suggest that the Ultrio Elite should theoretically be able to detect HCV at 5252.7 cps/mℓ 
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which far above both ID50s for HCV.  Not all low viral load samples tested reactive; four samples with 
viral loads higher than 4176 cps/mℓ tested non-reactive.  
The lowest viral loads that were found reactive were far above the infectious dose level for HCV 
therefore transmission would not be prevented based on DPS NAT only. The study of a bigger sample 
size could reduce the uncertainty of this conclusion. 
 
4.3.1.4 Sample stability after three weeks 
The S/CO change observed for all three reactive samples tested three weeks after preparation are 
within the intra-run standard deviation for each virus. Therefore, the change in the S/CO is not significant 
and the results could imply that DPS is stable for at least three weeks at room temperature. This finding 
is supported by a number of articles where stability using DBS/DPS is only affected at higher 
temperatures and longer storage periods. (Cassol et al., 1991; Abe and Konomi, 1998; Bennett et al., 
2012; Stene-Johansen et al., 2016).  These findings should not be used in isolation as the sample size 
for stability testing was very limited and the viral loads of the samples tested were relatively high.  Higher 
viral loads are generally more stable than lower viral loads (Stene-Johansen et al., 2016). 
 
4.3.1.5 Discriminatory probe (dHXV) 
dHXV is designed as a follow-up probe for discriminating reactive samples after confirmed reactive 
Ultrio Elite test results. In this study all samples with sufficient volume that tested non-reactive on Ultrio 
Elite where nevertheless tested with dHXV, and some were subsequently found to be reactive. Thee of 
the nine samples for DBS and three of the 17 samples for DPS that tested non-reactive with Ultrio Elite 
tested reactive on dHXV. This is most likely due to low viral loads that are seen and not due to increased 
specificity of the discriminatory probe as the only assay where the dHXV probe has a higher sensitivity 
is dHIV (Gen-Probe, 2012).  
 
4.3.1.6 Negative and Positive Predictive Value  
The negative and positive predictive values of DBS/DPS, taking prevalence into account, are equal to 
those currently observed using plasma samples.  PPV, without reference to prevalence is lower for DBS 
than for DPS within Cohort B.  NPV and PPV, using the claimed plasma sensitivities and WPBTS donor 
population, were calculated to be 100%, which is higher than those calculated for both DBS and DPS.  
NPV is predominantly based on specificity and prevalence while PPV is predominantly based on 
sensitivity and prevalence.  Therefore when evaluating an assay for routine use, it important to ensure 
that the NPV/PPV is calculated using the parameters that are relevant to the testing facility to ensure 
that the NPV/PPV is acceptable.  
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4.3.2 Specificity 
Specificity of a screening assay in a blood transfusion setting is not only important because it correctly 
identifies a donor as not being infected with a virus, but an assay with poor specificity also results in 
additional expenses.   
Additional expenses arise from the chain of events after an initial reactive result is determined. Once a 
sample tests initially reactive will have to be repeat-tested.  If the repeat test results are reactive (or on 
initial results depending on the algorithm) the associated blood products will have to be discarded. So 
evidently the additional expenses would consist of repeat testing, confirmatory testing, and the donation 
set.   
The largest cost to a blood transfusion service is often overlooked - this cost results from the loss of 
potential income from the sale of the blood products and the potential loss of a donor. When a blood 
unit tests reactive, whether it be a true infection or a cross-reactive result, it is mandatory to discard 
such a unit.  Therefore the unit of blood cannot generate an income. Furthermore, the donor is 
blocked/deferred for a specific length of time from donating blood which results in a loss of donated 
blood in addition to the cost for the confirmatory testing needed to reintroduce the donor back into the 
blood donor pool, on a subsequent donation.  If inconclusive results (or true reactive results) are 
obtained it is also possible that a previous donated unit will be investigated and that a look-back 
procedure could be initiated.  In most cases, a look-back procedure would entail contacting all recipients 
of the previous unit in question and performing a specific blood test on these donors to determine 
whether they have contracted the transfusion transmissible infection. The additional level of safety 
gained by performing a look-back procedure addresses concerns about donors being in the window 
period of an infection at the previous donation. 
The Ultrio Elite assay claims 100% specificity (95% CL: 98.2% to 100%) on plasma samples (Gen-
Probe, 2015).  In real-life use, the WPBTS has observed an average specificity of 99.97% (95% CL: 
99.96% to 99.97%) on 465 234 samples tested during the last 3 years (2015 - 2017). 
The algorithm used in this study stipulates that if a sample was found initially reactive but non-reactive 
on repeat testing, it is regarded as non-reactive.  In contrast, the WPBTS algorithm deems these donors 
as IR-NRR and counts them as false reactive because units are discarded based on the initial result.  
Should we have employed the WPBTS algorithm on this study the two initially reactive DBS samples 
would have been considered as false reactive, and the specificity for Ultrio Elite would have been 
calculated to be 99.78% for DBS (95% CL: 99.20% to 99.97%) and 100% for DPS (95% CL: 99.59% to 
100.00%).  However, if the specificity is calculated based on the algorithm used during this study, the 
resulting specificity for both DBS and DPS is 100% (95% CL: 99.59% to 100.00%).  
NAT specificity is not only impacted by the prevalence of the diseases that are tested for, but also by 
the overall prevalence of diseases within a population. The rule of thumb is the higher the overall 
prevalence of viruses the higher the risk of a donor having circulating viral DNA or RNA from viruses 
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other than HIV, HBV or HCV which could result in cross-reactive results.   
The Ultrio Elite assay states that an albumin level of 60 g/ℓ or higher could result in cross-reactive results 
(Gen-Probe, 2015). The normal average serum-albumin level is 40 g/ℓ (Margarson MP and Soni N., 
1998) with a reference range of 3.4 to 5.4 g/dℓ.  Fifty to sixty percent of the total protein in plasma is 
Albumin (Margarson MP and Soni N., 1998; Devaraj and Wheeler, 2015; Greco, Frank and Walton-
Ziegler, Olivia, 2018).  Therefore the normal reference range falls below the interference level.  
However, a study performed in Ghana to establish population-based reference ranges suggested that 
the reference range for serum-Albumin in Ghana should be 46 – 68 g/ℓ (Koram et al., 2007), thus placing 
the Ghanaian normal reference range above the interference level.  Koram et al. suggest that the 
differences seen between the stated reference ranges and the normal values obtained could be due to 
the fact that the standard published reference ranges are based mostly on Caucasian sample 
populations, in addition to which genetical and environmental factors might play a role.  This illustrates 
how important it is for each laboratory to establish their own data-sets using samples from the general 
population that the laboratory intends to screen. 
 
4.3.2.1 S/CO value comparisons 
The lack of red blood cells and the similarity of sample composition results in DPS and traditional plasma 
samples sharing a number of characteristics. Both DPS and plasma sample S/CO values are lower, 
with smaller standard deviations (see FIGURE 3.1). Each data set has a right-tailed S/CO distribution 
indicative of a higher frequency of low S/CO values than high S/CO values. The first quartile for the 
DBS dataset is higher than the third quartile of both the plasma and DPS samples. A lower and tighter 
S/CO distribution has the advantage of ensuring ease of interpretation of sample results and reducing 
the number of borderline results.   
The difference between DPS and plasma samples, and DBS samples is most likely due to the presence 
of haemoglobin in the DBS samples.  When the red blood cells dry, on the filter paper, the red cells 
lyse.  The free haemoglobin is then eluted from the paper during the elution process. This is the only 
variable that is present in DBS, but not in DPS or plasma, since neither the plasma nor the DPS samples 
contain significant amounts of free-haemoglobin. Haemoglobin is primarily stored in red blood cells 
within the blood. The Ultrio Elite package insert notes that a haemoglobin content of 5000 mg/ℓ or more 
may cause interference of cross-reactivity (Gen-Probe, 2012). A minimum donation criteria is that each 
donor has a minimum haemoglobin level of 12.5 g/dℓ. This would result in 12.5 mg of haemoglobin 
present in the 100 µℓ whole blood used for making the DBS. This 12.5 mg of haemoglobin would then 
be placed in a 2 mℓ buffer solution for elution. This would then equates to 6250 mg/ℓ of haemoglobin.  
This minimum haemoglobin level (donors often have higher haemoglobin levels) is more than the level 
at which haemoglobin may cause interference or cross-reactivity. 
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4.3.2.2 Invalid results 
On the Panther analyser, an invalid result can be obtained for numerous reasons, from instrument 
failure, inadequate sample volume to internal control failure (IC invalid). Internal Control (IC) is added 
to the reagents to control nucleic acid capture, amplification, and detection.  For example, if the sample 
contains a substance that inhibits either one of these processes, the signal of the internal control will 
be below the calculated IC cut-off for samples, and therefore the result will be regarded as invalid. The 
type of invalid results observed with the DBS samples during this study were IC failures. During 2017, 
87 IC invalid results were recorded at WPBTS during the routine screening of 153 947 donors. This 
amounts to an IC invalid rate of 0.06% for routine screening of plasma compared to the 0.50% invalid 
rate seen using DBS. If DBS was used for routine screening throughout 2017, there would have been 
a projected 770 invalid results. The reason for the high number of IC invalid results seen using DBS 
samples is most likely due to interference from haemoglobin. 
 
4.3.3 Contamination Panel 
Within SSA, facilities are usually not purpose-designed for transfusion testing. Instead existing 
infrastructure is adapted in a more or less suitable way.  Under these conditions tests and processes 
have to be as robust as possible, and ideally should not require additional contamination precautions.  
The ‘contamination panel’ consisting of forty samples was run blind, i.e. expected results were made 
available only after the testing was completed and results were compiled.  The samples were handled 
as routine samples following the protocol set out in the methods section, with no additional precautions 
to limit contamination.  All the samples were run by the same technologist. 
Lack of contamination indicates that both sample preparation protocol and tests were robust.  A 
confounding factor could be that all samples were run and prepared by the same technologist who has 
15 years of good laboratory practice (GLP) experience. This human resource may not be available in 
most SSA laboratories. 
 
4.3.4 Statistical Analysis 
4.3.4.1 Accuracy 
Although no official recommendations are available for the accuracy of blood transfusion screening 
tests, accuracy does provide an overall view of how well an assay performs.  DBS samples had a 
slightly higher accuracy (98.45 %) than DPS samples (97.80%).  This could be due to a larger number 
of HBV NAT yield samples included in the DPS samples than the DBS samples. This is the only metric 
where DBS samples apparently outperformed the DPS samples. 
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4.3.4.2 Bland Altman 
When comparing the two different dried spot samples against the plasma “gold standard” there was no 
interpretational difference in Cohort A for both DBS and DPS testing when following the design of this 
study.   
Using the Bland Altman analysis a bias was observed between plasma S/CO and DBS S/CO values. 
The bias increases as the S/CO values increase.  A large number of S/CO values fall outside the 95% 
limits of agreement (LOA), this indicates that a correlation between the plasma S/CO values and DBS 
S/CO values does not exist. 
Using the Bland Altman analysis no bias was observed between the plasma S/CO and DPS S/CO 
values. Almost all of the S/CO values fall inside the 95% LOA indicating that there is a correlation 
between the plasma S/CO and DPS S/CO values. 
 
4.3.4.3 Cohen’s Kappa coefficient 
Cohen’s Kappa is a statistical measure that is used to measure the agreement between two categorical 
datasets with an expected dichotomous outcome. 
Within this study the agreement was found to be 98.45% between plasma S/CO and DBS S/CO values. 
The Cohen’s Kappa coefficient (CKC) was equal to 0.8615. Below in Table 4.1 Landis and Koch 
suggests the following values for interpretation. Which means that the agreement is almost perfect. 
Table 4.1. Cohen’s kappa coefficient interpretations as described by Landis and Koch (Landis 
and Koch, 1977) 
COHEN’S KAPPA COEFFICIENT Agreement 
0.00 Less than chance 
0.00 – 0.20 Slight 
0.21 – 0.40 Fair 
0.41 – 0.60 Moderate 
0.61 – 0.80 Substantial 
0.81 – 1.00 Almost perfect 
 
Within this study the agreement was found to be 97. 80% between plasma S/CO and DPS S/CO values. 
The CKC was equal to 0.8645. Which means that the agreement is almost perfect.   
The plasma-DBS S/CO values comparison had a lower CKC than that of the plasma-DPS S/CO values 
comparison, showing that the plasma S/CO and DPS S/CO values had a greater agreement. We 
Stellenbosch University  https://scholar.sun.ac.za
51 
 
choose to interpret this as an indicator that DPS samples are better suited for testing than the DBS 
samples. 
 
4.4 PRACTICAL APPLICATION 
One of the main questions this study set out to answer is whether DBS/DPS would be suitable for blood 
donor screening using Ultrio Elite as ID-NAT screening assay on the Panther systems.  This questions 
will now be discussed from several practical perspectives. 
To make NAT feasible, centralised NAT testing would have to be performed. The two main advantages 
of centralised testing are that 
1. better quality assurance (QA) can be established and maintained (procedures, policies and 
testing can be better controlled.)  
2. and that testing would be cheaper, due to economies of scale. 
 
4.4.1 Quality Assurance 
The success of NAT within SSA would be heavily dependent on the QA. QA should not only be applied 
to testing laboratories but to all blood transfusion activities. QA measures should include but will not 
necessarily be limited to: 
 Adequate training of staff regarding: 
o Donor interviewing 
o Collecting DBS/DPS 
o Processing the DBS/DPS samples for testing 
o Testing samples on the Panther analyser 
 Accurate recording of results and other information  
 Adequate documentation of processes and procedures 
 Adequate retention and retrieval of documents 
 Safe working conditions 
 Adequate personal protective equipment 
 Adequate documentation with regard to change management 
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4.4.2 Collection and processing of DBS and DPS 
4.4.2.1 Sample preparation 
When looking at sample collection, DBS samples are the easiest to obtain. Capillary blood can be 
applied directly to the DBS card after a copper sulphate test or other appropriate test for haemoglobin 
has been performed by means of a finger prick. A foreseen risk is that the incorrect DBS sample 
application could render the sample unsuitable for testing, thus making the donation unusable.  
In our study we found that DPS samples provide better results than DBS samples. DPS samples require 
a venous sample to be taken and centrifuged prior to DPS sample preparation. The addition of collecting 
plasma in a tube for DPS would add to overall costs. Additional infrastructure and supplies would also 
be needed.  The following additional items would be needed to prepare a DPS sample (that are not 
required when preparing a DBS sample): 
1. Hypodermic needles 
2. Specimen tubes with caps 
3. Centrifuge (Which either require a battery or electricity) 
The additional step of using a venous plasma sample could result in incorrect sample labelling and 
sample mix-up in the pre-analytic area.  Plasma samples are lighter in colour than whole blood, and 
thus visual confirmation that the sample was applied to the DPS card is not as prominent as whole 
blood applied to a DBS card.   
Roche diagnostics (Mannheim, Germany) has designed a novel DBS card that produces a DPS, this 
present a possible solution to many of the challenges faced preparing DPS in rural areas. It is called 
the Cobas® Plasma Separation Card (Roche Diagnostics, Mannheim, Germany). This card claims to 
have detected a viral load of 91.5 cps/mℓ when using it in combination with the COBAS® 
AmpliPrep/COBAS® TaqMan® HIV-1 Test (Roche, 2017).   
Once the DBS/DPS cards are prepared there is no difference in the preparation of the sample.   
During this study, samples were allowed to air dry on the bench making use of empty Panther tip trays.  
The holes for the tips in these trays ensured that the cards dried adequately due to good ventilation. 
The good ventilation also made it possible to stack the trays, thus conserving space. Repurposing these 
trays was a cheap, durable option as the Panther tip trays are generally discarded once the tips have 
been used. The reuse of Panther tip trays is a scalable solution since trays could be sent from the 
central testing laboratory to the rural areas with the sample collection transport. During this study the 
laboratory temperature was controlled, but in a number of studies DBS has been shown to be stable at 
temperatures above room temperature.  The effect of humidity in transport without climate control could 
be reduced by placing desiccants in the shipping container/bag. 
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4.4.2.2 Laboratory results  
Overall, our study found DPS to be a better sample than DBS with regard to laboratory results.  
DPS samples had greater sensitivities and specificities, had fewer invalid results, less initial-reactive-
non-repeat-reactive results, lower S/CO values for negative samples, and their S/CO values were more 
comparable to plasma S/CO values than DBS.  The increased sensitivity of DPS is probably due to the 
larger plasma input volume.  
The Invalid result rate of the DBS would not result in an efficient testing management as it is 
approximately ten times more than the average invalid rate seen within WPBTS.  Should DBS be used 
an invalid result could mean that insufficient volume would be available for discriminatory testing if an 
initial invalid sample was found to be subsequently reactive.   
 
4.4.3 Testing strategies 
Blood screening services usually test their complete TTD test panel simultaneously using samples 
taken at the same time as the blood unit is collected (World Health Organization, 2010).  Novel 
strategies suggest a number of various combinations which include sequential testing of TTD markers 
and using rapid testing prior to donation. Both of these strategies are aimed to reduce costs. When 
sequential testing strategies are employed cost is saved by not testing all the deemed markers if a unit 
is reactive, in other words only negative units would have been tested against the full testing panel. 
Rapid testing pre-donation is not recommended by the WHO (World Health Organization, 2010; Bloch, 
Vermeulen and Murphy, 2012), but this strategy does reduce costs as a blood collection set is not 
“wasted” as a reactive donor is deferred prior to donating.  It also has the marginal benefit of allowing 
donors to be counselled immediately if they test reactive for a TTD marker.  Additional safety can be 
built into the rapid test screening strategy by adding additional post-donation testing.  Some studies 
have looked at the viability of combining rapid tests and NAT testing (van Hulst M, Owusu-Ofori S, 
Sarkodie F, Nsiah-Asare A, Candotti D,Postma MJ, 2008; El Ekiaby, Lelie and Allain, 2010) for blood 
screening. Both these studies concluded that this testing strategy would not compromise safety and 
would reduce testing costs.  The combination of rapid tests and NAT testing has not been limited to 
blood transfusion but has also been documented in the diagnostic field (Kania et al., 2013).   
 
The true benefit of NAT is the identification of blood donations during the window period or occult phase 
of viral infection thus reducing the risk of transmission.  By investigating the use of DBS and DPS for 
NAT testing, this study was able to demonstrate that the Ultrio Elite was able to detect an HIV-1 window 
period sample.  HIV-2 was not included in this study as the donor demographics of the WPBTS does 
not include HIV-2 donors.  If this sample type (DBS/DPS) is to be used in areas where HIV-2 is endemic 
further analysis and studies need to be performed.  Window period HBV infections are not often seen 
at WPBTS as seroprevalence for anti-HBc is high in the general population base. Therefore, a 
combination of window period and occult HBV samples was used for the study. Ultrio Elite, was not 
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reliably able to detect the NAT only HBV infections using DBS or DPS samples. No HCV window period 
samples were tested, both DBS and DPS samples had a 100% sensitivity for concordant HCV. 
 
Individual testing strategies and testing algorithms must be evidence-based and cognisant of the 
national and regional epidemiology of TTD. The epidemiology studies should be conducted on both 
first-time and repeat donors. 
 
4.4.4 Transport 
Transportation within SSA, where distances are long and roads are not always well maintained, poses 
one of the greatest hindrances to centralised testing. The cost of transporting plasma samples from 
rural areas to centralized testing centres would require specialized vehicles that could maintain the cold 
chain of the samples, and also be equipped for biological safety precautions as liquid samples (which 
could be infectious) would be transported.  This would result in added costs and could potentially delay 
the availability of blood. If DBS/DPS samples were transported no or minimal cold chain management 
would be required, and samples would carry a low infectious risk (Bond et al., 1981).  Samples could 
even be mailed, although this strategy could introduce delays to testing to such an extent that test 
results might not be available when the unit is required. 
One of the developments with regard to transportation of blood products is the utilisation of unmanned 
aerial vehicles (also referred to as drones) as currently used in Rwanda and Tanzania.  In Rwanda 
drones routinely deliver units of blood. These drones can fly within an average radius 80 km, and reach 
their destinations within in 30 minutes.   
Taking into account the carrying capacity of such a drone (1.8 kg) and the weight of a DBS/DPS sample 
card (+/- 2g), approximately 900 DBS/DPS cards (with no packaging added) could be transported 
(Zipline, no date; Rosen, 2017) in a single flight.  DBS/DPS cards could then be flown to centralised 
laboratories and tested. Results could then be sent back to the peripheral collection centres. Drones in 
Tanzania are also used to deliver urgent medical supplies, and thus present the case that such drones 
could also be employed to deliver blood from peripheral centres to rural hospitals thus reducing delivery 
time (Zipline, no date; Amukele et al., 2017; Rosen, 2017; Becker, 2018). Currently the drones used by 
Zipline are deployed for a delivery form a centralised base after a sms is sent from the requesting 
hospital. 
As illustrated, the use of DBS/DPS for testing opens up various transportation solutions much better 
suited for SSA. 
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CHAPTER 5  
4. CONCLUSION 
Innovative screening strategies such as pre-donation rapid testing followed by NAT testing at a 
centralized site (van Hulst M, Owusu-Ofori S, Sarkodie F, Nsiah-Asare A, Candotti D,Postma MJ, 2008) 
could revolutionise the safety of blood screening even in resource-constrained settings.  One of the 
largest hindrances, apart from training, in the above strategy would be transportation from donation site 
to the centralised laboratory.  
DBS/DPS samples can be transported with no or minimal cold chain management, and carry a low 
infectious risk (Bond et al., 1981). Should DBS/DPS samples yield comparable test results to plasma 
samples, they would pose a viable, transportable specimen that could be processed and tested in a 
centralised laboratory. Using DBS/DPS samples would reduce some of the costs associated with NAT 
testing. 
This study found that the diagnostic specificities of both DBS and DPS samples were equal to that of 
plasma samples, thus indicating that either would be a reasonable tool for screening of donated blood. 
However, the sensitivities for both HCV and HIV were lower using DBS/DPS samples than for plasma 
samples. This was expected for samples with such small input volumes and large dilutions. The HBV 
reactive DBS/DPS samples showed very erratic results which render them unsuitable for testing; further 
development of the assay to increase the sensitivity to HBV would be recommended. 
DPS performed marginally better than DBS, and would be suited for screening blood, especially if the 
HBV sensitivity of the assay were to be increased. Further detailed economic viability and large-scale 
studies need to be performed to determine sensitivity and specificity within a specific population. 
With regard to sample integrity, both DBS and DPS displayed reliable results even after a three week 
period of storage at room temperature. An additional advantage of collecting dried blood or plasma 
specimens on cards is that collection costs and complexity would be reduced.  
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ADDENDUM C.  CONTAMINATION PANEL RESULTS 
 
 
 Ultrio Elite original sample interpretation Virus DPS Interpretation 
A001 Nonreactive N/A Nonreactive 
A002 Reactive HIV Reactive 
A003 Nonreactive N/A Nonreactive 
A004 Reactive HIV Reactive 
A005 Reactive HCV Reactive 
A006 Nonreactive N/A Nonreactive 
A007 Nonreactive N/A Nonreactive 
A008 Reactive HBV Reactive 
A009 Nonreactive N/A Nonreactive 
A010 Reactive HBV Reactive 
A011 Reactive HIV Reactive 
A012 Reactive HCV Reactive 
A013 Reactive HBV Reactive 
A014 Reactive HCV Reactive 
A015 Nonreactive N/A Nonreactive 
A016 Reactive HIV Reactive 
A017 Reactive HIV Reactive 
A018 Reactive HIV Reactive 
A019 Reactive HBV Reactive 
A020 Nonreactive N/A Nonreactive 
A021 Reactive HIV Reactive 
A022 Reactive HBV Nonreactive 
A023 Reactive HIV Nonreactive 
A024 Nonreactive N/A Nonreactive 
A025 Reactive HCV Reactive 
A026 Reactive HBV Reactive 
A027 Reactive HBV Nonreactive 
A028 Nonreactive N/A Nonreactive 
A029 Reactive HIV Reactive 
A030 Nonreactive N/A Nonreactive 
A031 Reactive HCV Reactive 
A032 Nonreactive N/A Nonreactive 
A033 Reactive HIV Reactive 
A035 Reactive HBV Reactive 
A036 Reactive HIV Reactive 
A037 Reactive HBV Reactive 
A038 Reactive HIV Reactive 
A039 Reactive HCV Reactive 
A040 Nonreactive N/A Nonreactive 
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ADDENDUM D.  RESULTS OF PROCURED HIV-SAMPLE DILUTIONS 
Serial Number 
Viral Load 
(cps/mℓ) 
Dilution Dilution factor 
Calculated viral load 
present in DPS eluted 
sample (log units) 
DPS Result 
S/CO 
HIV1 
101000 1 20 3.70 9.88 
50500 2 20 3.40 10.16 
25250 4 20 3.10 9.64 
12625 8 20 2.80 7.8 
6312.5 16 20 2.50 4.22 
3156.25 32 20 2.20 1.62 
1578.12 64 20 1.90 3.25 
789.06 128 20 1.60 1.18 
394.53 256 20 1.30 0.18 
197.27 512 20 0.99 0.05 
HIV2 
193000 1 20 3.98 11.54 
96500 2 20 3.68 12.03 
48250 4 20 3.38 11.68 
24125 8 20 3.08 12.17 
12062.5 16 20 2.78 12.08 
6031.25 32 20 2.48 7.42 
3015.625 64 20 2.18 9.55 
1507.8125 128 20 1.88 4.94 
753.90625 256 20 1.58 0.05 
376.953125 512 20 1.28 2.05 
HIV3 
326000 1 20 4.21 12.52 
163000 2 20 3.91 11.01 
81500 4 20 3.61 11.72 
40750 8 20 3.31 11.66 
20375 16 20 3.01 11.26 
10187.5 32 20 2.71 9.03 
5093.75 64 20 2.41 9.89 
2546.875 128 20 2.10 7.97 
1273.44 256 20 1.80 4.31 
636.72 512 20 1.50 0.09 
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ADDENDUM E.  COMBINED S/CO FOR HIV PROCURED SAMPLES (N=30) 
 
 
ADDENDUM F. RESULTS OF DOUBLING SERIAL DILUTIONS OF PROCURED HBV 
REACTIVE SAMPLES 
Serial number Dilution 
Calculated 
cps/mℓ 
Log of Calculated 
cps/mℓ 
Dilutional 
factor 
DPS Result 
S/CO 
HBV1 
1 135520000 8.13 20 14.78 
2 67760000 7.83 20 13.99 
4 33880000 7.53 20 15.03 
8 16940000 7.23 20 15.41 
16 8470000 6.93 20 13.87 
32 4235000 6.63 20 13.82 
128 1058750 6.02 20 14.14 
512 264687.53 5.42 20 11.96 
HBV2 
1 110320000 8.04 20 14.92 
2 55160000 7.74 20 14.75 
4 27580000 7.44 20 14.27 
8 13790000 7.14 20 15.41 
16 6895000 6.84 20 14.86 
32 3447500 6.54 20 13.93 
128 861875 5.94 20 14.62 
512 215468.74 5.33 20 13.84 
HBV3 
1 868000000 8.94 20 14.51 
2 434000000 8.64 20 14.83 
4 217000000 8.34 20 14.79 
8 108500000 8.04 20 15.01 
16 54250000 7.73 20 14.89 
32 27125000 7.43 20 14.09 
128 6781250 6.83 20 14.44 
512 1695312.5 6.23 20 14.46 
 
y = 4.3725x - 9.745
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ADDENDUM G.  RESULTS OF TEN-FOLD SERIAL DILUTIONS MADE FROM PROCURED 
HBV REACTIVE SAMPLES 
Serial 
Number 
Dilution 
Calculated 
cps/mℓ 
Calculated 
cps/mℓ 
Dilutional 
factor 
DPS Result 
S/CO #1 
DPS Result 
S/CO #2 
HBV01 
10 13552000 7.13 20 15.34 14.28 
1000 135520 5.13 20 16.15 13.85 
10000 13552 4.13 20 0.03 12.04 
100000 1355.2 3.13 20 0.04 0.03 
HBV02 
10 11032000 7.04 20 16.05 15.12 
1000 110320 5.04 20 15.41 15.61 
10000 11032 4.04 20 0.05 5.79 
100000 1103.2 3.04 20 0.03 0.78 
HBV03 
10 86800000 7.94 20 15.16 14.48 
1000 868000 5.94 20 15.95 14.76 
10000 86800 4.94 20 14.5 14.62 
100000 8680 3.94 20 0.03 0.04 
 
ADDENDUM H. SCATTER PLOT OF ALL RESULTS OF PROCURED HBV-SAMPLE 
DILUTIONS (N=48) 
 
  
y = 2.5429x - 3.6556
0
5
10
15
20
25
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
U
lt
ri
o
 E
lit
e 
S/
C
O
Log10 cps/mℓ present in plasma sample
Stellenbosch University  https://scholar.sun.ac.za
67 
 
ADDENDUM I.  RESULTS OF PROCURED HCV-SAMPLE DILUTIONS 
Serial 
Number 
Dilution 
Calculated 
cps/mℓ 
Log of Calculated 
cps/mℓ 
Dilutional 
factor 
DPS Result 
S/CO 
HCV1 
1 1067800 6.03 20 9.69 
2 533900 5.73 20 9.56 
4 266950 5.43 20 9.46 
8 133475 5.13 20 9.84 
16 66737.50 4.82 20 9.41 
32 33368.75 4.52 20 0.29 
64 16684.38 4.22 20 0.14 
128 8342.19 3.92 20 0.51 
256 4171.09 3.62 20 0.71 
512 2085.55 3.32 20 0.3 
HCV2 
1 4598000 6.66 20 9.98 
2 2299000 6.36 20 9.42 
4 1149500 6.06 20 10.04 
8 574750 5.76 20 9.36 
16 287375 5.46 20 9.82 
32 143687.50 5.16 20 0.84 
64 71843.75 4.86 20 1.55 
128 35921.88 4.56s 20 3.17 
256 17960.94 4.25 20 3.9 
512 8980.47 3.95 20 4.17 
HCV3 
1 2128000 6.33 20 9.84 
2 1064000 6.03 20 9.84 
4 532000 5.73 20 9.51 
8 266000 5.42 20 9.86 
16 133000 5.12 20 7.06 
32 66500 4.82 20 1.44 
64 33250 4.52 20 1.72 
128 16625 4.22 20 2.48 
256 8312.50 3.92 20 2.51 
512 4156.25 3.62 20 2.58 
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ADDENDUM J.  SCATTER PLOT OF RESULTS OF PROCURED HCV-SAMPLE DILUTIONS 
(N=30) 
 
 
 
 
y = 3.6636x - 12.63
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